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ABSTRACT 
The assessment of fat absorption forms an important part of the diagnostic 
process in some patients being investigated for possible malabsorption. This 
study has assessed the use of 13C-triolein as an alternative to the current 14C_ 
triolein test for fat absorption. 
Initial work required an evaluation of performance characteristics of the 
isotope ratio mass spectrometer, observations on the normal variation in the 
exhaled breath 13C02: 12C02 ratio over one day, ie, the effect of food and 
exercise, the investigation of a number of potential test meals to aid isotope 
delivery and the effect of 13C dose. A protocol has been developed for a test 
of fat absorption using 13C-triolein as the marker substrate and lemon mousse 
as the test meal. 
Breath samples from 18 healthy volunteers and 26 patients with potential fat 
malabsorption referred by the gastroenterologists, were studied after the 
ingestion of lemon mousse and 200 JlL 13C-triolein. Breath samples were 
taken before ingestion and for six hours after ingestion and analysed. This 
data has been compared with results of samples obtained using the 14C_ 
triolein test of fat absorption performed on the same patients at the same 
time. There was a significant difference between the peak DOB of the male 
and female volunteers (p = <0.05). In patients, lower peak DOB were 
observed in those with suspected fat malabsorption, than in those patients 
with normal fat absorption (p = <0.005). 
xi 
Results are discussed in terms of a 13C-triolein breath test using a lemon 
mousse fat meal as a simple non radioactive test for fat malabsorption. 
However, a larger clinical trial of patients is now required to confirm these 
initial results. 
xii 
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1 AIM 
To develop a fat absorption test based on 13C-triolein which could be used in 
hospitals and Primary Care as an alternative to using radioactive 14C-triolein 
because of concerns of radioactivity and to improve patient acceptability. 
1 
2 IYTRODUCTION 
The quantitative measurement of fat in the faeces of patients in order to 
assess malabsorption was first described in 1914 (1). Since that time, the 
assessment of fat absorption and malabsorption has continued to be used as 
. 
a marker of gastrointestinal function in clinical practice.... In this Introduction, a 
brief account of dietary fat and the processes involved in fat absorption, are 
given as background to the more clinical sections. These describe current 
diagnostic tests for assessing fat absorption and the place of isotopes in the 
evaluation of gastrointestinal function. 
2.1 DIETARY FAT 
Humans usually eat a mixed diet which, for continuing good health, must 
contain the following basic constituents: proteins, fats, carbohydrates, mineral 
salts, vitamins and water (2). Fat as a food has more energy (39 kJ/g) weight 
for weight, than any other dietary component (2). Fats are normally stored in 
.. 
the body as an energy reserve; subcutaneous fat also provides individuals 
with a layer enabling them to retain heat. Certain fats are also essential 
constituents of cells notably as components of membranes and neurological 
tissue. 
Dietary fats are divided into two main types, animal fats and vegetable fats. 
Animal fats are largely mixtures of stearic, palmitic and oleic acids combined 
with glycerol as triglycerides and are obtained from meat and dairy produce. 
Butter contains 80% fat and double cream is 40% fat (2). Vegetable fats are 
found in plants, especially in seeds and nuts, for example, sunflower seeds, 
2 
olives aoo rapeseed. They are consumed in the diet in cocoa, chocolate, 
cooking '(lils, salad oils and in small amounts in some vegetables. Cooking 
oils are almost 100% fat and contain a mixture of triglycerides specific to the 
plant species from which the oil is derived. A comparison of fatty acids found 
in common cooking oils is shown in Table 2.1. 
Table 2.1 - Comparison of fatty acids in some animal and vegetable fats 
(percentage composition by weight) (4) 
%COMPOSITION (BY WEIGHT) OF FA TTY ACIDS 
SA TURA TED ACIDS UNSATURA TED ACIDS 
PALMITIC STEARIC OTHER OLEIC LINOLEIC OTHER 
Animal fats: 
- Chicken fat 25.6 7.0 0.3 39;3 21.8 5.9 
- Beef fat 29.2 21.0 3.4 41.1 1.8 3.5 
Vegetable oils: 
- Corn/maize 8.1 2.5 0.1 30.1 56.3 2.9 
_A Olive oil 10.0 3.3 0.6 77.5 8.6 <0.1 
On a typical Western diet, a human adult ingests about 100g of fat (40% of 
the energy required per day), of which 92% to 96% are long chain 
triglycerides. The rest is mostly phospholipids (1 to 2 9 per day), and free and 
esterified cholesterol (3). Dietary fat is thus mainly composed of triglycerides. 
In the bowel, dietary lipids are mixed with another 50 to 60 g of endogenous 
lipids originating from the bile (bile salts, phospholipids and cholesterol), 
desquamated cells (mixed membrane lipids) and dead bacteria. Cholesterol 
3 
in the intestinal lumen is derived from bile salts and from the diet; only about 
30% of clietary cholesterol is absorbed (3). The fat in faeces, around 4 g per 
day in the healthy adult, is derived relatively equally from dietary, biliary, 
cellular and bacterial sources (7). The low faecal excretion shows the 
efficiency of the overall process of fat digestion and ab...,sorption in the healthy 
adult. In children who are growing faster, the demand for energy and efficient 
fat absorption is even greater. The fat intake needed in a newborn baby 
would be equivalent to an adult ingesting 300 to 500 g of fat per 70 kg of body 
weight (3). 
Fatty acids consist of an alkyl chain with a terminal carboxyl group, the basic 
formula of completely saturated species being CH3-(CH2)n-COOH; Most fatty 
acids in humans have 16, 18 or 20 carbon atoms. The names and structures 
of some typical fatty acids that are of importance to humans are shown in 
Table 2.2. 
Table 2.2 - Some fatty acids of importance to humans (5) 
COMMON NUMERICAL STRUCTURE SYSTEMA TIC NAME 
NAME SYMBOL 
Palmitic acid 16:0 CH3-(CH2)wCOOH Hexadecanoic acid 
Stearic acid 18:0 CH3-(CH2)16-COOH Octadecanoic acid 
Oleic acid 18:1(9) CH3-(CH2h-CH=CH-(CH2)- cis-9-0ctadecenoic acid 
COOH 
Linoleic acid 18:2(9,12) CH3-(CH2h-«CH2-CH=CH)z- cis, cis-9-12-
(CH2h-COOH Octadecadienoic acid 
Linolenic 18:3(9,12,15) CH3-(CH2-CH=CHh-(CH2h- cis, cis, cis-9, 12, 15, 
acid COOH Octadecatrienoic acid 
Arachidonic 20:4(5,8,11,14 ) CH3-(CH2h-(CH2-CH=CHk cis, cis, cis, eis, 5,8,11, 
acid (CH2h-COOH 14-Eicosatetraenoic acid 
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2.2 PROCESSES INVOLVED IN THE DIGESTION AND ABSORPTION 
OF DIETARY FAT 
Normal intestinal absorption of dietary fat in man depends on adequate 
digestion of food. This requires normal pancreatic function, a normal area of 
functioning intestinal cells and the presence of bile salts. The absorption of 
cholesterol, phospholipids and fat soluble vitamins depends on normal 
triglyceride absorption (6). This process will be expanded on later. 
Malabsorption of fat, therefore, occurs when there is impaired function of the 
pancreas, or when the surface area available for absorption is reduced or 
when the concentration of the luminal bile salts is low. 
The gastrointestinal organs and their functions are shown diagrammatically in 
Figure 2.1. Digestion begins as the mechanical process of the mastication of 
food, mixed with saliva, starts to reduce the size of the food particles (7). 
Lingual lipase is secreted by the dorsal surface of the tongue, this enzyme 
initiates lipid digestion. 
In the stomach, secretion of hydrochloric acid in the gastric juice leads to 
acidification of the stomach contents and the "churning" process further 
breaks food particles down. Chyme is the name given to the partly digested 
food as it issues from the stomach into the intestine (4). It is semi liquid in 
consistency, with a pH of less than 2. 
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Figure 2.1 - Gastrointestinal organs and their functions (5) 
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Food is fiJlly digested and absorbed in the small intestine. The common bile 
duct add"s bicarbonate from pancreatic secretions which neutralises the acid 
from the stomach and increases the pH of chyme to about 6-7. At this pH 
dietary triglycerides are split by the lipases produced by the pancreas into 
. 
glycerol and fatty acids. Large globules of fat are redt,U;ed in size to a fine 
emulsion by the action of bile which increases the surface area leading to 
greater efficiency in the catalytic activity of the lipases at the water/lipid 
interface. 
There are three distinct phases in the process of fat absorption (8), the 
intraluminal phase, the mucosal phase and the intracellular phase. 
2.2.1 The intraluminal phase 
The intraluminal phase involves 4 lipases and 1 cofactor in the process of 
lipolysis. 
Lingual lipase functions in the acid pH of the stomach and plays a 
significant part in the hydrolysis of dietary fat. It also promotes the 
binding of colipase to pancreatic lipase and aids in liberating 
cholecystokinin-pancreozymin (CCK-PZ) from the duodenal mucosa, 
which stimulates gall gladder contraction and bile flow and increases 
the secretion of pancreatic enzymes (6). 
Pancreatic lipase functions at a pH of 6 to 6.5 in the duodenum, 
catalysing the hydrolysis of triacylglyerols to free fatty acids and 2-
monoglycerols. It acts at the waterllipid interface of the emulsion 
7 
droplets. The concentration of lipase in the duodenal contents during 
digestion of a test meal is about 0.1 mg/mL. For a meal with a volume 
of 2,000 mL this is equivalent to 200 mg lipase. 200 mg of lipase can 
hydrolyse 540 9 of triglycerides to diglycerides in 1 minute (8). As a 
normal meal contains about 30 9 of triglycerides there is more than 
enough lipase to hydrolyse dietary fat in a very short time. 
Colipase binds to pancreatic lipase enabling lipase to compete at the 
water lipid interface with bile salts. Colipase is initially secreted in the 
pancreatic juice as a non-active form but is then activated by trypsin. 
Deficiency of colipase has been reported to lead to malabsorption of fat 
(8). 
Pancreatic carboxylester lipase, a non specific lipase in pancreatic 
juice, hydrolyses various neutrallipids, including fat soluble vitamin 
esters. This lipase is also known as bile salt stimulated lipase, 
cholesterol ester hydrolase or monoglyceride lipase. An 
immunologically identical enzyme is present in human milk and the milk 
of some primates (8). 
Phospholipase A2 is also found in pancreatic juice and is activated by 
trypsin. It catalyzes the hydrolysis of phospholipids, mainly 
phosphatidylcholines, to their Iyso-forms and to free fatty acids (8). 
8 
Micelles are formed when the products of lipolysis, ie, fatty acids, 
monoglycerides, Iysophospholipids and cholesterol, mix with the bile salts in 
solution in the small intestinal lumen. These micelles range in size between 
40 and 60 Jlm depending on bile salt concentration and the ratio of bile salts 
to lipids. They are a bilayer disc with a band of bile salts on their outer edge 
and other more hydrophobic components protected within the interior (See 
Figure 2.2), (6). 
Figure 2.2 - Structure of an intestinal micelle (5) 
Bila 
sail 
9 
Phospholiplds Monoacyf-
glycerol 
2.2.2 The mucosal phase 
The mucous membrane in the intestine is the surface layer of epithelial cells 
covered with mucous together with the underlying fibrous tissue. There are 
two barriers to the uptake of nutrients from the lumen of the small bowel into 
the epithelial cells of the mucous membrane: 
Firstly, there is a diffusion barrier caused by "unstirred water" over the 
surface layer of epithelial cells; this prevents transport from the bulk 
phase of the intestinal contents to the cell membrane. The flux through 
this layer of water and mucous is a function of the concentration 
gradient across the layer and the permeability of the layer. The latter is 
determined by the thickness of the layer and the aqueous diffusion 
coefficient of the molecules in question. 
The second barrier is the cell membrane itself. 
The fatty acids, monoacylglycerol, phospholipids and cholesterol protected 
within the micelles are able to pass through these two barriers from the lumen 
of the small bowel into the epithelial cells. 
2.2.3 The intracellular phase 
Monoglycerides and fatty acids from lipolysis are the main lipids entering the 
cytoplasm of the cells within the mucosa of the small intestine. Under the 
electron microscope, fat is initially visualised within the endoplasmic reticulum. 
A fatty acid binding protein with a molecular weight of 12,000 has been 
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isolated from the enterocyte cystosol, which has a role in the transport of fatty 
acids from the membrane to the endoplasmic reticulum (8). The intracellular 
process includes the resynthesis of fatty acids and monoglycerides into 
triglycerides principally by the monoacylglycerol pathway catalysed by 
triacylglycerol synthetase shown diagrammatically in Figure 2.3. 
The resynthesised triglycerides are delivered to the lymphatic vessels as 
chylomicrons. Chylomicrons have a diameter of 1 J.lm and in addition to 
triglycerides contain other absorbed lipids including cholesterol, fat soluble 
vitamins, and phospholipids, and some protein. The chylomicrons are 
transported from the abdominal lymphatic vessels via the thoracic duct to the 
systemic circulation from where they can then be assimilated into the 
metabolic processes of the body. 
2.2.4 Absorption of medium chain fatty acid triglycerides 
The processes described in Sections 2.2.1 to 2.2.3 are applicable to long 
chain triglycerides, however, the absorption of medium chain fatty acid 
triglycerides (MCT, triglycerides with fatty acids of chain length C8 to C12), is 
achieved through a different pathway. MCTs are hydrolysed by pancreatic 
lipase in the lumen more effectively than long chain triglycerides and their 
absorption is independent of bile (4). 
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Figure 2.3 - Processes involved in the transfer of dietary fat from the intestinal 
lumen to the lymphatic ducts (5) 
Dietary Fat (Triacylglycerol) 
! Pancreatic lipase 
2 Fatty acids 
Enterocytes of 
Intestinal wall 
2 Fatty aCid. 2 CoA 
2 Fatty acyl - CoA 
Lymph 
duct 
+ 
Monoacylglycerol Monoacylglycerol I ---::::oo~~::t- glycerol + 
Triacylglycerol 
_-,-I ~.~ Chylomicron --1--' Chylomicrons 
• 
Intestinal 
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After entry into the mucosal cells, fatty acids from dietary MCTs are 
transported to the portal blood and leave the intestine as free fatty acids partly 
bound to albumin. Of the MCTs, only the C12 fatty acids are found in the 
chylomicrons and in the adipose tissue or other lipid stores. Shorter chain 
length fatty acids (CB, C10) are rapidly metabolised to carbon dioxide and 
water in the liver. 
In summary, dietary fat is composed mainly of non polar, long chain 
triacylglycerols which are virtually water insoluble. In this form fat is not 
available for digestion in the intestinal tract. The gastrointestinal tract 
secretes enzymes causing the lipolysis of fat and their conversion to more 
polar products which are then able to mix with water. Bile disperses the 
products of lipid digestion and helps overcome the diffusion barrier covering 
the mucous membrane of the small intestine. 
2.3 THE CLINICAL PICTURE OF MALABSORPTION OF FAT AND 
OTHER DIETARY CONSTITUENTS 
A patient with a mild case of malabsorption may complain to the doctor of 
vague abdominal symptoms and perhaps the common complaint of feeling 
"tired all the time". Routine laboratory tests will probably show normal results 
apart from anaemia, ie, a low blood haemoglobin concentration (6). 
In severe and long standing generalised fat malabsorption, whether intestinal 
or pancreatic, the clinical picture may include generalised wasting and 
malnutrition (due to deficiency of proteins and fat soluble vitamins), 
13 
osteoporosis and osteomalacia (protein and calcium deficiency), oedema 
~-. 
(hypoalbuminaemia due to protein deficiency) and tetany (hypocalcaemia due 
to vitamin D and calcium deficiency) (6). 
If fat malabsorption is severe, the patient will complain .... of foul smelling, bulky, 
pale, greasy stools which are difficult to flush down the toilet. This condition is 
known as steatorrhoea. Significant steatorrhoea is defined as a daily faecal 
fat excretion consistently more than 14 g of fat (6). 
Typical laboratory findings include (6) increased fat in the stools, anaemia 
(iron and/or folate and/or vitamin B 12 deficiency), hypocalcaemia with 
hypophosphataemia, raised plasma alkaline phosphatase activity from clinical 
or sub clinical osteomalacia and rickets, a low concentration of serum albumin 
and prolonged prothrombin time caused by vitamin K deficiency. 
the malabsorption of fat leads to the malabsorption of fat soluble vitamins A, 
D, E and K contained in the diet. 
Vitamin A deficiency is rarely clinically evident in the United Kingdom (UK). In 
a Western diet, vitamin A is usually present in more than ample quantity and 
is stored in the liver. Many foods contain vitamin A, including carrots, egg 
yolk, liver, milk, butter and most green vegetables (6). 
Vitamin D is formed naturally in the fatty tissues of the body when the skin is 
exposed to the action of daylight. Vitamin D deficiency, due either to 
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malabsorption or to dietary deficiency is common in the UK. Cod liver oil is 
one of the few foods that contain vitamin D naturally. Other foods, for 
example, margarine and breakfast cereals, contain added vitamin D in order 
to prevent deficiency. Vitamin D deficiency results in impaired calcium 
absorption. A low ionised serum calcium concentration stimulates parathyroid 
hormone secretion, which by causing phosphaturia, leads to 
hypophosphataemia and then to osteomalacia and rickets, and to 
osteoporosis (6). 
In contrast, to vitamin D, vitamin K is present in many dietary constituents, 
being found in spinach, leafy vegetables, tomatoes and liver. It is needed for 
the hepatic synthesis of prothrombin and other clotting factors. A bleeding 
tendency associated with a prolonged prothrombin time, may develop in 
patients with severe fat malabsorption. This prothrombin deficiency, unlike 
that due to liver disease, can be reversed by parenteral dosage of vitamin K 
(6). 
The malabsorption of fats and fat soluble vitamins is often accompanied by 
the maldigestion or malabsorption of dietary proteins. For example, in 
pancreatic disease, the digestion of protein is severely impaired due to the 
deficiency of proteolytic enzymes in addition to the reduction in the output of 
lipolytic enzymes. This can lead eventually to generalised muscle and tissue 
wasting, to osteoporosis and a reduced level of all protein fractions in the 
blood plasma. A low plasma albumin concentration may cause oedema and a 
reduction of plasma total calcium concentration. Reduced antibody formation 
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(immunoglobulins) may make a patient more susceptible to infection. In 
intestinal disease, amino acid and peptide malabsorption may occur in 
addition to fat malabsorption, due to impaired intestinal transport 
mechanisms. 
2.4 CURRENT TESTS FOR ASSESSING THE ABSORPTION AND 
MALABSORPTION OF FAT 
Fat malabsorption thus has significant immediate and long term clinical 
consequences. There is therefore a need for clinicians to be able to identify 
patients with fat malabsorption in order to diagnose and then treat the 
underlying cause. 
A wide variety of methods have been used in clinical laboratories to assess fat 
absorption. They can be divided into two groups depending on the methods 
involved. There are those that measure fat excretion in faeces and those that 
measure fat absorption after an oral "test meal". The latter methods involve 
measurement of metabolic products in blood, urine or breath after the 
consumption of the test meal. 
2.4.1 Measurement of fat excretion in faeces 
Fat in faeces is present principally as triglycerides, free fatty acids or soaps. 
Triglycerides in faeces contain mainly long chain fatty acids and are derived 
from dietary fat which has not been absorbed or from intestinal secretions. 
The latter are the main source in a healthy individual but in steatorrhoea, 
excess fat is of dietary origin (9). The fatty acids are produced by the luminal 
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hydrolysjS of triglycerides by pancreatic lipase and by bacterial enzyme 
action. Soaps, present in the faeces, are the sodium, potassium and calcium 
salts of fatty acids. 
Bowel action is irregular and assessment of fat in a 24 hour stool collection 
." 
does not provide adequate discrimination between normal and abnormal fat 
excretion. Most quantitative measurements of fat in faeces are therefore 
made on a 3 day faeces collection. Analyses of total fat content is then 
carried out on a faecal homogenate with fat being detected by either titration 
or infrared spectroscopy. In the traditional faecal fat procedure, alkaline 
hydrolysis (saponification) of neutral fats produces glycerol and soaps. After 
acidification, the fatty acids are extracted into light petroleum ether and 
quantified by titration (9). 
The use of infrared spectroscopy for faecal fat determination is relatively new 
(9) and not widely used in clinical laboratories in the UK. In this procedure, 
after extraction, using acidified petroleum ether-ethanol, the fatty acids are 
dried and dissolved in chloroform. An infrared spectrum is recorded in the 
range 4,000-650-1 cm and absorbance data used to calculate faecal fat 
excretion (10). 
Another method is the detection of fat globules in a random faecal sample. 
After vigorous mixing, a small sample of the faeces is placed on a slide, 
stained with Sudan III and examined under a light microscope for fat globules 
(11). The "steatocrit" procedure is another simple method. A random faecal 
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sample is collected and 0.5 g is diluted with two volumes of water. This is 
homogenised and an aliquot transferred to a haematocrit tube. After 
centrifugation, three layers are produced; a lower solid layer (S), an 
intermediate liquid layer and an upper fatty layer (F). The lengths of the 
layers are measured and the "steatocrit" calculated as a percentage (12) as 
follows: 
Steatocrit = F x 1001 (F + S) 
Prior acidification of stool improves the recovery of the fat. The normal adult 
range is 8-23%. In pancreatitis and in small bowel disease (12) the range is 
approximately 20-70%. 
2.4.2 Measurement of fat absorption after a "test meal" 
Tests that assess fat absorption after an oral "test meal" can be divided into 
those that require the collection of blood or breath samples for analysis. The 
"butter fat" test involves the measurement of chylomicrons by turbidity or the 
analysis of triglycerides in blood serum. The butter fat test was developed by 
Bentley, Eastham and Lane in 1975 and involves the patient fasting for 12 to 
14 hours (13). A fasting blood sample is taken and the serum separated. The 
patient then ingests a meal consisting of 50 mL of unsweetened orange juice, 
2 slices of buttered toast (0.5 g butter per kg body weight) and unsweetened 
tea or coffee. A second blood sample is taken 2 hours later and the serum 
separated. The sera are then diluted and the Light Scattering Intensity (LSI) 
measured in a nephelometer which indicates the chylomicron concentration 
as a measure of absorbed fat (9). 
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The 14C-triolein breath test (14) assesses malabsorption using a pre-prepared 
fat meal. This is the current method used by many hospitals including 
Derbyshire Royal Infirmary (ORI). After fasting overnight, a baseline breath 
sample is taken followed by ingestion of a meal containing 19.3 g of fat and 
185 kBq 14C-triolein. Breath test samples are then collected over the following 
6 hours. Levels of labelled 14C02 in the breath samples are measured using a 
scintillation counter. Generally, 14C-triolein is used as the fat marker in 
preference to 14C-tripalmitin or 14C-trioctanoin (15). The Ouncan survey (16) 
showed that UK laboratories using this procedure all administer similar 
amounts of radioactivity, ie, 5 J.lCi (185 kBq) per patient, although the amount 
of fat given varies from 0.5 g to 60 g per patient. Triolein breath tests are 
influenced by the amount and type of calories given in the accompanying 
meal (17). A fat intake of 0.5 g does not represent a realistic fat challenge but 
increasing the calorific intake of food either as fat or carbohydrate inhibits 
metabolism of the labelled fat (18). Newcomer (15) showed that the peak of 
14C02 was lower and occurred three hours later when a 50 g fat meal was 
given instead of 20 g. Ouncan in 1992 (17) Similarly demonstrated that with a 
60 g fat meal, the production of C02 was delayed with only 42% of subjects 
reaching a peak by the ninth hour. Cumulative 14C02 excretion gave a better 
discrimination. He concluded that the triolein breath test was preferable to 
faecal fat measurement. He noted that it avoids the unpleasant faecal 
collection and analysis for the patient and laboratory staff, provides results the 
following day, is well tolerated by patients and is easily performed on an 
outpatient basis. 
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2.4.3 Tests of fat absorption used to assess pancreatic function 
The tests described in the preceding 2 sections are all tests which assess the 
overall process of fat absorption, however, there are also methods that look 
specifically at pancreatic function. In the Pancreolauryl Test, urine is collected 
from the patient on two separate days following ingestion of test meals. On 
the first day, 2 slices of buttered bread are eaten with 350 mg of fluorescein 
dilaurate which is a substrate for pancreatic lipase. On the second day, 2 
slices of buttered bread are eaten with unesterified fluorescein. On both days 
urine is collected for 10 h following ingestion of the test meals (19). 
Fluorescein is a harmless, colourless dye which becomes orange green and 
fluoresces at an alkaline pH, and can be measured by spectrophotometry or 
fluorimetry. The amount of fluorescein excreted in the urine after oral 
ingestion of the dilaurate is an indication of pancreatic digestion. The 
absorption and excretion of free fluorescein on day 2 is used to control for any 
changes in small bowel absorption or renal excretion of the dye. A normal 
pancreolauryl excretion index (expressed as fluorescein excreted on Day 1 as 
a percentage of that excreted on Day 2), suggests that the patient does not 
have chronic pancreatic disease or at least not in a sufficiently advanced form 
to reduce the exocrine secretion to less than 5-10% of normal. An abnormal 
result suggests further investigation is required (ultrasound scanning) to 
separate the true from the false positives. 
Another non invasive test of pancreatic lipase activity in the duodenum is the 
13C mixed chain triglyceride breath test, (20). This test uses 1,3-distearyl, 
2[carboxyl-13C] octanoyl glycerol which contains a 13C stable isotope labelled 
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medium chain fatty acid in the 2 position and long chain fatty acids in the 1 
and 3 positions. The rate limiting step in the digestion of the mixed 
triglyceride is hydrolysis of the two stearyl groups by pancreatic lipase. 
CH20COR1 
I 
CHO*COR2 
I 
CH20COR3 
R1 and R3 = stearic acid (18:0) 
R2 = octanoic acid 
The pancreatic lipase cleaves the octanoic acid. The absorption of octanoic 
acid is not dependent on micelle formation. The 13C-octanoic acid is oxidised 
via acetyl CoA to 13C02. The 13C mixed chain triglyceride breath test 
assesses the levels of intraluminal pancreatic lipase whereas the 14C-triolein 
fat absorption test provides a global assessment of fat absorption. 
2.4.4 Review of the performance of tests used to assess fat absorption 
Analytical performance of most tests carried out in clinical chemistry 
laboratories in the UK is monitored through the UK National External Quality 
Assurance Scheme programmes (NEQAS), initially set up in the late 1960s. 
Laboratories have to subscribe to this programme as one of the criteria for 
accreditation with the Clinical Pathology Accreditation Board. The scheme 
covers most biochemical analytes, so that laboratories can monitor their own 
analytical performance against other laboratories with the objective of 
continual quality improvement. Until recently, the NEQAS scheme however, 
did not cover tests for gastrointestinal function. In order to assess the need to 
include gastrointestinal tests within the range of procedures included in the 
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NEQAS scheme, Dr Duncan of Glasgow Royal Infirmary, carried out a 
comprehensive survey of gastrointestinal function testing in hospital 
laboratories in 1997 on behalf of the Association of Clinical Biochemists and 
the British Society of Gastroenterology. A total of 233 laboratories and 330 
clinicians took part in the survey which highlighted significant problems in the 
way that many of these tests for fat absorption were carried out (16). 
The survey showed that a wide variety of tests were used to assess fat 
absorption in the UK. The faecal fat test described by van de Kamer et al. in 
1949 (21) was the most widely available test and was used by 67% of 
gastroenterologists responding to the questionnaire. 
In normal health, faecal fat is largely derived from endogenous rather than 
dietary sources. Adequate dietary fat intake is therefore essential if false 
negative results are to be avoided. The British Society of Gastroenterology 
guidelines recommend a diet containing at least 70 g of fat for 6 days (22). 
However, in the UK only 20% of laboratories attempted to ensure adequate 
fat intake of patients undergoing this test. A further source of error noted was 
that patients with steatorrhoea may reduce their fat intake to control their 
diarrhoea which could lead to falsely low results. 
When the titration step of the faecal fat test was evaluated in an external 
quality assessment, between laboratory CVs for three samples ranged from 
31 to 42% (16). The main reason for the wide analytical variation was that 
82% of the laboratories surveyed had no internal quality control procedures 
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for faecal fat analysis. Also as there was no external quality control scheme, 
the laboratories had no comparative data to use to monitor the validity of their 
results. Infrared spectroscopy has recently been described as an alternative 
analytical procedure which should give improved CVs but there will still be 
problems of dietary input and sample collection (10). The equipment needed 
for infrared spectroscopy is not available in most clinical laboratories at 
present in the UK. 
The faecal microscopy test was used by 43% of clinicians. A disadvantage of 
this test is that as faecal fat excretion is a function of dietary fat intake (23), 
malabsorbing patients on a low fat diet will produce a normal result. The 
Duncan survey (16) showed that in 91 % of laboratories providing the faecal 
microscopy test, fat intake was not controlled, so that false negative results 
were likely. This test is qualitative rather than quantitative and the visual 
examination by microscopy is a subjective measurement. Several members 
of staff analysing samples also contributed to the wide variability in results 
(24). 
The fat load or butter fat test has some advantages over the other tests in that 
the procedure is very simple, no complex analytical procedures are required, 
and there is no need for faecal collections. This test was only available in 
21 % of laboratories and was used by just 11 % of clinicians, and where 
available was only requested, on average, once every two weeks. Wide inter-
laboratory variations in the test protocol with differences in the type of fat used 
and in the times of blood collection were reported (15). The approved 
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protocol used 0.5 g fat/kg body weight in the form of butter with collection of 
blood at zero and 2 hours. This test protocol, however, has been shown (13) 
to give very unsatisfactory results, with large overlap between normal subjects 
and patients with malabsorption. When choosing biochemical tests their 
sensitivity, (the fraction of those with a specific disease that the assay 
correctly predicts) and their specificity, (the fraction of those without a specific 
disease that the assay correctly predicts) are compared (25). The fat load 
test has poor sensitivity unless fat malabsorption is severe and in addition the 
false positive rate was high. The low sensitivity and specificity of the test 
make it unsuitable for routine use. 
The Pancreolauryl Test was available in 60% of laboratories surveyed (16). 
Analysis of urinary fluorescein is simple and CVs between laboratories was 
acceptable at 10%. The test is inconvenient for the patient, because urine is 
collected over 2 days and the patient must drink large volumes of water on 
both days of the test. It is however useful in detecting pancreatic exocrine 
deficiency, with the sensitivity of 85% and specificity of 88%. Clinicians 
should be aware that false positive results may occur after vagotomy, 
cholecystectomy or biliary bypass surgery (6). Normal results may be found if 
pancreatic disease is mild. The Pancreolauryl Test is not a "global" test for fat 
malabsorption, because it assesses only the intraluminal lipolysis step. 
The 14C-triolein breath test is a simple method of assessing fat malabsorption 
but was only used by 9% of clinicians (16). The main disadvantage is that the 
test uses a radioactive isotope and is therefore unsuitable for the investigation 
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of premenopausal women or children. In addition, scintillation counters are 
not available in many hospitals. Several papers note that the excretion rate of 
14C02 is influenced by the endogenous production rate of carbon dioxide (17, 
26, 27). They report that this should to be corrected for by measuring carbon 
dioxide output which can vary considerably between patients. The survey 
(16) found that no laboratories measured C02 output. In practice, C02 
production was assumed on the basis of body weight (9 mmollkg/h) or a 
correction was made for body surface area. 
The 14C-triolein breath test has many advantages over other tests for fat 
malabsorption. As triolein is a long chain triglyceride the test assesses the 
whole process of fat absorption, ie, it is a global fat absorption test. It is 
simple to perform and can be easily performed in an outpatient clinic setting. 
The 14C-triolein test has been used in the author's hospital, Derbyshire Royal 
Infirmary (DRI), since 1985. In an evaluation of 57 patients, a sensitivity of 
85% and a specificity of 93% were found for the detection of fat malabsorption 
(14). However, with the need to reduce the use of radioactive isotopes the 
use of this test should be minimised. 
2.5 USE AND MEASUREMENT OF ISOTOPES IN 
GASTROENTEROLOGY 
Isotopes are atoms of the same element that differ in atomic mass, due to 
differences in the number of neutrons. The three most abundant isotopes of 
carbon are carbon 12 C2C) which contains 6 neutrons; carbon 13 C3C) which 
has 7 neutrons; and carbon 14 C4C) which has 8 neutrons (28). Having too 
25 
few or too many neutrons compared to protons causes isotopes, such as 14C 
to be unstable. These unstable radioisotopes will decay to stable products. 
Other isotopes such as 12C and 13C do not decay because their particular 
combinations of neutrons and protons are stable. On earth 98.89% of carbon 
found is 12C and 1.11 % is 13C (29) with only trace quantities of 14C. 
Both radioactive and stable isotopes are currently used in the investigation of 
gastrointestinal disease. They are regularly used in gastroenterology to label 
substrates which are then used as tracers for the investigation of metabolic 
pathways, to measure body composition, energy balance, protein turnover 
and fuel metabolism (29). 
2.5.1 Radioactive isotopes 
A list of procedures used in gastroenterology using substrates labelled with 
radioactive isotopes is shown in Table 2.3. Care has to be taken not to 
administer them to children, to pregnant women or to women of child bearing 
age who may become pregnant. There are also many regulations governing 
all aspects of the use, administration to patients and disposal of radioactive 
materials (14). 
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Table 2.3 - Some radioactive isotopes used diagnostically in 
gastroenterology (3D) 
ORGAN SUBSTRATE MAIN USE 
Small bowel 14C-D-xylose Bacterial overgrowth 
Small bowel 75 Selenohomocholyltaurine Bile acid malabsorption 
Intestinal 14C-triolein Fat absorption 
Intestinal 14C-trilinolenin Fat absorption 
Intestinal 14C-tripalmitin Fat absorption 
Intestinal 57 Co or 58CO 812 Vitamin 812 absorption 
Colon 1111n white cells Inflammatory bowel disease 
The radioactive vitamin 812 test is an example of the use of a nonstable 
isotope. It is used to identify those patients with a deficiency of intrinsic factor. 
Vitamin 812 contains cobalt and may be labelled by incorporating either 57 Co 
or 5aCo into the molecule (3D). 
Leucocytes labelled with 1111ndium are used in the investigation of 
inflammatory bowel disease, both for establishing the presence of the disease 
and in assessing its activity, particularly in acute disease or when an abscess 
or fistula are suspected. The labelled leucocytes have a half life of 7 hours 
and migrate to the areas of infection thus highlighting the inflammation. 
Images are taken after 4 hours in cases of inflammatory bowel disease and 
after 24 hours if an abscess is suspected (3D). 
As has already been described the 14C-triolein breath test is used to assess 
fat absorption (13). Following ingestion of 14C-triolein with a test meal, 
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patients ,are asked to breathe into a vial containing a fixed amount of alkali 
.... -:-
... 
(hyamine) solution to trap exhaled CO2. The vial also contains an indicator to 
show that the predetermined amount of CO2 (usually 2 mmol) has been 
trapped. The amount of 14C present can then be determined by liquid 
scintillation counting in a beta counter. It is necessaryJo assume a basal rate 
of C02 production (9 mmol/kg/h) in order to express the results as a 
percentage of the amount of 14C administered (see Appendix 1). 
2.5.2 Stable isotopes 
Radioisotopes have been widely used, however, increasing awareness of 
environmental issues and the regulatory control of these compounds have 
stimulated the search for alternatives. 
Stable isotopes fulfil many of the requirements needed for an ideal marker for 
use in a clinic setting. They are non radioactive, and can safely be 
• 
administered to young and old, to male and female. The sample collection is 
simple, the tests are repeatable and provide a non invasive way of assessing 
gastrointestinal function (31). The disadvantage is the detection of a small 
change relative to large background levels of stable isotopes. 
Stable isotopes do have limitations, they are more expensive to purchase 
than radioactive isotopes and require specialist apparatus for testing 
enrichment. Also 13C02 breath tests are performed with a large natural 
abundance of 13C (1.1 %) which could lead to errors when identifying changes 
due to ingestion of 13C. 
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Table 2.4 - Some stable isotopes used diagnostically in gastroenterology (32) 
ORGAN SUBSTRATE MAIN USE 
Stomach 13C-urea Detection of Helicobacter pylori 
Stomach 13C-acetate Gastric emptying (liquids) 
Stomach 13C-octanoate Gastric emptying (solids) 
Small bowel 13C-lactose Lactose tolerance 
Small bowel 13C-xylose Small bowel overgrowth 
Small bowel 13C-lactose-ureide Transit time 
Liver 13C-aminopyrine Liver function 
Liver 13C-caffeine Liver function 
Intestinal 13C-glycocholic acid Bile acid malabsorption 
Pancreas 13C-hiolein Pancreatic function test 
Pancreas Glycerol-1,3,distearyl-2- Pancreatic function test 
13C-octanoate 
Pancreas Cholesteryl 13C-octanoate Pancreatic function test 
Pancreas 13C-starch Pancreatic function test 
The 13C urea breath test is probably the most widely used stable isotope test. 
It is used for the detection of Helicobacter pylori, a common cause of 
histological gastritis and the causative organism of most peptic ulcer disease 
and gastric cancer (33). The bacteria has extremely high urease levels which 
is the basis of the diagnostic test for detecting abnormal gastric colonisation 
(34). After an oral dose of the 13C urea, 13C02 rapidly increases in 
concentration in the breath of Helicobacter pylori positive subjects as the 
organism splits the urea, producing 13C-labelled bicarbonate in the stomach, 
which is absorbed into the blood and exhaled as 13C02. The breath 13C02, 
15 minutes after ingestion of a capsule containing 13C urea, is compared with 
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the basal breath 13C02. The 13C02: 12C02 ratio is measured by isotope ratio 
mass spectrometry (IRMS) (see Appendix 2). 
The 13C-hiolein breath test (mixed long chain triglyceride uniformly labelled 
[98%] with 13C) is a non radioactive test for exocrine pancreatic insufficiency 
(35). The fatty acid composition of the hiolein is shown in Table 2.5. 
Table 2.5 - Fatty acid composition of hiolein (35) 
FATTY ACID % 
Oleic (C18:1) 51 
Linoleic (C18:2) 20 
Palmitic (C16:0) 17 
Other C18 5 
Other C16 4 
Other (unspecified) 3 
This test has similar methodology to the urea breath test. A standard rice 
snack (1.5 g per kg of patient weight) is ingested with 2 mg per kg labelled 
hiolein. Then 13C02: 12C02 enrichment in exhaled breath is measured by 
IRMS. 
The lactose breath test is used by clinicians to detect patients who are unable 
to digest lactose due to lactase deficiency. The 13C -lactose breath test has 
advantages over unlabelled lactose, which is used in the hydrogen breath test 
for lactase deficiency The recovery of the carbon isotope in breath 13C02 
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after digestion, absorption and metabolism of the labelled disaccharide in the 
.-:-
If' 
small intestine is a more direct measure of lactase activity than the 
measurement of hydrogen liberated by the fermentation of unabsorbed 
disaccharide by colonic flora in the large bowel (31). The methodology is 
similar to the above two examples. 
2.5.3 Principles of isotope ratio mass spectrometry 
In the 1950s geochemists first began investigating stable isotopes in rocks 
and soils. Detecting small differences in the natural abundance of stable 
isotopes can help test hypotheses about the history of the earth. High 
precision measurements were needed but speed of results was not so 
important. Geochemists might only analyse 10 samples a day. Biologists 
have different requirements, they use materials which are artificially enriched 
with stable isotopes as tracers of natural cycles and pathways. They may not 
need such high precision instrumentation but they do need the ability to run 
~ 
large numbers of samples with adequate precision. 
The basis of mass spectrometry is the production of ions from neutral 
compounds and the examination of the subsequent fragmentation of those 
ions (36). A substance can be characterised by investigating the distribution 
of ions resulting from that substance. As the technique involves a chemical 
reaction, the sample being investigated is not recoverable but this is not 
usually a problem as only a very small quantity of the material is needed for 
the analysis. As with any chemical reaction, the precise outcome, the mass 
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spectrum, is dependent on a number of factors such as temperature, 
~-:-
.... 
concentration and effects of the medium (36). 
As can be seen in Table 2.4 substances labelled with 13C are commonly used 
in clinical investigations. In organic matter about 1.1 %..of carbon is 13C. 
When a relatively 13C rich substrate is ingested, it will be digested and 
absorbed and the 13C will then enter into oxidative metabolic pathways 
leading to enrichment of bicarbonate, protein, fat and carbohydrate within the 
body. The breath will be enriched with 13C02 relative to the basal situation. 
Breath can be collected and treated to separate CO2 from other components, 
and the proportion of 13C02 measured by gas isotope mass spectrometry. 
Figure 2.4 shows a schematic of the BreathMAT IRMS used in this study. 
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3 OBJECTIVES 
To develop a test that will: 
Eliminate the use of radioactive material 
Be as accurate as the radioactive method (see Appendix 14C fat 
absorption test. 
Be simple in method to enable any health care professional to perform 
the test. 
Be "patient friendly" 
Simple sample collection 
The current study set out to assess the possibility of using a 13C-labelled long 
chain triglyceride as a marker of fat absorption and malabsorption in the 
clinical setting. Previous local experience has been with a comparable 14C-
labelled substrate (Appendix 11), which was used as a "gold standard" in 
studies in patients described in this thesis. 
The objective of this thesis has been to develop a 13C-based test for fat 
absorption in humans. 
The use of 13C substrate would eliminate the use of radioactive materials. 
The aim has been to develop the test which would be as accurate as the 
current radioactive method C4C fat absorption test, see Appendix 11). The test 
should also be simple in method and sample collection to enable any health 
care professional to perform the test. The test needs to be "patient friendly" to 
ensure attendance and compliance with dietary restrictions. 
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4 ME.THODS AND MATERIALS 
.... 
4.1 MATERIALS 
4.1.1 Chemicals 
13C-Triolein: Glycerol [1 ,1'1,,_13C] trioleate, catalogue numb.er CLM-163. 
Cambridge Isotope Laboratories, Andover, Mass, USk' 
14C-Triolein; glycerol tri [1_14C] oleate, code CFA 258,9.25 MBq, 3.7 
MBq/mL. Amersham Pharmacia Biotech, Little Chalfont, Bucks. 
Carbon Dioxide, 652 Grade 4.5, (reference CO2 for BreathMAT), Air Products 
plc, Basingstoke. 
Ethyl alcohol, absolute. Hayman Limited, Eastways Park, Witham, Essex. 
Helium 689 Grade A. BOC, Manchester. 
Hydroxide of hyamine 10x (diisobutyl-cresoxyethoxyethyl) 
dimethylbenzyl-ammonium hydroxide, 1 M solution in methanol, Canberra 
Packard, Brook House, Pangbourne. 
Olive oil, Co-op, extra virgin. 
Scintillant, Emulsifier Safe, Canberra Packard, Pangbourne, Berks. 
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Thymolphthalein crystalline (5' ,5"-diisopropyl-2' ,2"-dimethyl-phenolphthalein), 
Sigma, Aldrich Company Limited, Fancy Road, Poole, Dorset. Prepared as a 
500 mg/L solution in ethyl alcohol. 
4.1.2 Foods used to aid isotope delivery 
Lemon mousse, see Appendix VII. 
Chunky Kit Kat (55 g). Nestle. 
Duobar, natural flavour (45 g). SHS International Limited, Liverpool. 
Scandishake, strawberry flavour (85 g). SHS International Limited, 
Liverpool. 
4.1.3 Apparatus 
BreathMAT Plus, Isotope ratio mass spectrometer. Finnegan MAT, GmbH, 
Bremen, Germany. 
Drinking straws. Labco Limited, Bucks. 
Exetainers, 10 mL glass tubes with gas tight caps. Labco Limited, Bucks. 
Hair dryer. 
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One way valves, XCO 160417 OD mm. Analytical Supplies Limited, 
Derby. 
Pipette 200 /-lL capacity. Fisher Scientific UK, Loughborough, Leics. Pipette 
tips, Universal disposable 0-300 ~L. Fisher Scientific UK. 
Scintillation Counter, TRICARB 2300TR. Canberra Packard. 
Scintillation Vials, Poly Q vials. Beckman R11C Limited, High Wycombe, 
Bucks. 
Teaspoon (household), stainless steel. 
Weighing boats, plastic. 
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4.2 METHODS 
4.2.1 Collection of breath samples 
The patient was instructed to inhale normally, then to hold their breath for 5 
seconds before exhaling. These instructions were identical for the collection 
of breath samples for the analysis of 14C02 and 13C02. 
4.2.1a Collection of breath samples for 14C02 analysis 
The patient exhaled through a straw assembly (see Appendix It) into 4 ml of 
a 50:50 mixture of 1 molll hyamine hydroxide and ethanol containing 100 J-ll 
of thymolphthalein solution in a scintillation vial. When the solution changed 
from blue to clear, 2 mmol C02 had been trapped. 
4.2.1 b Collection of breath samples for 13C02 analysis 
The subject exhaled through a straw into the bottom of an Exetainer tube. 
When condensation appeared on the sides of the tube, and exhalation was 
complete, the tube was capped and labelled. 
4.2.2 Analysis of 14C02 in breath samp'les 
In the 14C-triolein breath test, 185 kBq (5 J-lCi) 14C-triolein was given to the 
patient in a test meal of lemon mousse containing 19.3 g of fat. End 
expiratory breath CO2 was trapped by exhalation into hyamine hydroxide as 
described above. 10 ml of the scintillant Emulsifier Safe was added to each 
vial and 14C activity measured by liquid scintilliation counting. For further 
information, see 14C-triolein breath test Standard Operating Procedure (SOP) 
(see Appendix It). 
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4.2.3 Analysis of 13C02 in breath samples 
4.2.3a BreathMAT IRMS 
After collection of breath samples in Exetainers, the levels of 13C02 were 
analysed using the BreathMAT IRMS. For further information, see 
BreathMAT IRMS SOP, Appendix IV. 
4.2.3b Expression of 13C02 values 
Stable isotope abundances are expressed as the ratio 13C/12C in the sample 
compared with the same ratio in an international standard. 
The international standard for carbon is Pee Dee Belemnite (PDB). This is 
calcium carbonate (CaC03) from a cretaceous belemnite, Belemnitella 
americana from the Pee Dee formation in South Carolina, USA (37). The 
generally accepted absolute ratio of 13C/12C for PDB is 0.0112372 (29). 
The isotopic abundance for 13C02 in a standard gas or breath sample is 
expressed as the ratio of 13C/12C in parts per thousand ("per mil", %0) 
compared to the CO2 produced from PDB calcium carbonate. The "delta" (a) 
notation, in units per mil (%o) is used to express the difference in abundance 
between samples; thus PDB has a value of 0 and materials with ratios of 
more than 0.0112372 have positive delta values and those with ratios of less 
than 0.0112372 have negative delta values (29). 
The BreathMAT software uses the abbreviation Del13PDB to denote the 
difference of the sample 13C02 abundance from to PDB. This abbreviation is 
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therefore used throughout this thesis; alternatives in the literature are (513PDB, 
del13PDB or (513C. 
For comparison of sequential breath samples from one individual, the 
convention is to express the 13C02 abundances in parts per thousand relative 
to the baseline sample. The change from the baseline is described as DOB 
(ie, the change in the Del13PDB value of an individual sample from the 
Del13PDB of baseline sample; the "delta over baseline"). 
4.2.3c Maintaining analytical performance of 13C02 measurement 
The performance and precision of the BreathMAT has to be continually 
monitored to ensure accurate results. 
Peak shape stability and high voltage scan: the peak shape (see Figure 4.1) 
shows the intensity (mV) of the signals arriving at each cup (for mass 44, 45 
and 46) over a range of high voltage 2.765 to 2,810 volts. The upper trace is 
the ratio of masses 45/44. This upper trace can be expanded to observe the 
flatness of the ratio trace. This procedure was carried out every 3 months or 
after maintenance. 
Time scan: the signal stability (the drift or noise) can be observed using the 
time scan mode over 600 seconds. This procedure was completed every time 
the BreathMAT was used. The time scan should be horizontal (ie, no change 
in ratio over the 10 min period) and the amplitude (noise) of the signal should 
not exceed 0.001 (Figure 4.2). 
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Zero enrichment (internal reproducibility): to check internal reproducibility, the 
BreathMAT pre set sequence (C02zero 20) was run. The reference CO2 gas 
was sampled 20 times in sequence. This procedure was carried out every 3 
months or after maintenance. 
Precision (10 replicates of the same breath sample): to ensure the precision 
of the results the operator's own breath was collected in the prescribed 
manner into 10 separate Exetainers. These were sampled one after the other 
on the BreathMAT. 
Linearity correction: the measured sample Del13PDB value may be 
influenced by the total CO2 concentration of that sample. To ensure the 
precision of results over a range of C02 concentrations, a single sample of the 
operator's breath was sampled up to 10 times using a BreathMAT pre set 
sequence ("Multimet"), to provide a range of CO2 concentrations. 
When Del13PDB results were found to vary with CO2 concentration, a 
"linearity correction" was made following the manufacturer's instructions either 
manually or using software now available on the analyser. 
Between batch precision: to ensure that variation between batches of samples 
fell within acceptable ranges, the operator's own breath and three patients 
samples (DOB values <1, 1.0-2.0 and >5) were evaluated in 5 consecutive 
batches. 
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4.2.4 Development of fat absorption test using 13C-triolein 
4.2.4.1 a Assessment of the precision of dispensing 200 pL of olive oil 
The successive increases in weight as 200 Jll samples of olive oil were 
dispensed from a pipette on to a weighed plastic weighing boat were 
recorded. The mean, standard deviation and coefficient of variation were 
calculated. 
4.2.4b Breath 13C02:12C02 ratios; natural variation over one day 
The natural variation in 13C02: 12C02 ratios in breath samples over one day 
was determined by collecting breath samples in the prescribed manner 
(4.2.1 b) from a single subject every 30 minutes over the course of 1 day. 
Food and drink were consumed as normal. A note was made of the type of 
food consumed and of activities undertaken by the volunteer. All samples 
were collected in duplicate. Samples were evaluated on the BreathMAT 
IRMS, and the mean Del13PDB was calculated for each pair of samples. 
The first sample was taken as the baseline (the subject had fasted for 8 
hours). All subsequent samples were compared to this baseline value and 
results expressed as DOB %0. 
4.2.4c Breath 13C02:12C02 ratios; changes after ingesting various test 
meals to aid isotope delivery 
The subjects fasted overnight then after collecting a baseline breath sample, 
the test meal (see 4.1.2) was eaten and breath samples were collected over 
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the next 6 hours. The breath samples were collected in the prescribed 
manner, (4.2.1.b). 
4.2.4d Breath 13C02:12C02 ratios; changes after ingesting 200 pL 13C 
triolein with lemon mousse or Scandishake as the test meal 
The volunteers were identified and written consent obtained. In order to 
ensure that an adequate response was observed with a 200 III 13C-triolein 
dose, breath samples were collected and analysed in the prescribed manner 
over a period of 6 hours. They were allowed to eat a light lunch after 
completion of the 4 hour breath samples. 
4.2.5 Protocol for 13C-triolein fat absorption test 
The patient or healthy volunteer was identified and a letter given explaining 
the test and fasting requirements (subject fasted from midnight the night 
before the test, if the test is scheduled to start at 9.00 am). The subject was 
allowed to have a cup of tea before the test and a light lunch 4 hours after the 
start of the test; smoking was not permitted at any time. The amount of 
exercise during the time of the test was restricted. The breath sample 
containers were labelled clearly with bar codes and patient identifier. The 
collection of breath samples was explained to the patient, ie, take breath in, 
hold for 5 seconds, then blow into the tube. The first sample was taken and 
when condensation was seen on the glass and exhalation was complete, the 
cap was replaced. A duplicate sample was taken. These two samples were 
at time zero minutes. 
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The lemon mousse was obtained from the Catering Department at Derbyshire 
Royal Infirmary. To facilitate flow, 1 cm was cut from the end of the delivery 
pipette tip. 200 J!L 13C-triolein was dispensed into the spoon, which was 
placed in the lemon mousse. The patient ate the mousse and was asked to 
lick the spoon well to ensure complete ingestion of the substrate. Then 50 mL 
of water was drunk to wash the fat meal and substrate from the mouth. 
Duplicate breath samples were collected from the patient every hour for 6 
hours. A note was made of the patient's sex, age, weight and height. The 
breath samples were analysed on the BreathMAT IRMS. The protocol was 
approved by the Southern Derbyshire Local Research Ethics Committee and 
each subject provided written consent prior to undertaking the test. 
4.2.6 Evaluation of proposed protocol 
4.2.6a Healthy volunteers 
Twenty volunteers (all NHS employees) were recruited and written consent 
obtained. The 13C-triolein fat absorption test was carried out as above (4.2.5). 
The volunteer's Body Surface Area (BSA) and Body Mass Index (BMI) were 
noted. Using patients weight, height and a nomogram (51) BSA was 
calculated in square metres and BMI was calculated as weight (Kg)/height 
(m2). 
Two of the volunteers were re tested after a period of a few months to assess 
the reproducibility of the test. One ingested lemon mousse as the test meal, 
the other ingested Scandishake. 
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4.2.6b Patients 
Patients referred by gastroenterologists for the 14C-triolein fat absorption test 
as part of their clinical investigations, were asked for their written consent to 
also ingest 13C-triolein. Breath samples were then collected for both tests 
simultaneously, as described in the next section (4.2.6c). 
4.2.6c Method for the comparison of the 14C-trio/ein and 13C-trio/ein fat 
absorption breath tests 
The patients had been identified by consultant gastroenterologists as suitable 
for the fat absorption breath test (the patients were referred by Drs Freeman 
and Cole at Derby City General Hospital and Drs Holmes and Norton at the 
Derbyshire Royal Infirmary). Patient information sheets explaining the tests, a 
consent form and date of appointment were sent to the patient (Appendix V). 
The patient was allowed to have a cup of tea before the test and a light lunch 
4 hours after beginning the test. 
On arrival at the clinic, both tests were explained to the patient and written 
consent obtained. The sex, age, weight and height of the patient were noted. 
The breath sample containers were labelled clearly. The collection of breath 
samples was explained to the patient. At time 0 minutes, duplicate breath 
samples were collected following the prescribed procedures (see 4.2.1 a and 
4.2.1 b) to allow evaluation of baseline 14C02 and 13C02 levels. 50 III 14C_ 
triolein was dispensed on to a teaspoon. The carrier toluene was evaporated 
using a hair dryer on the cold setting. The patient ate half the lemon mousse 
with the 14C triolein coated spoon, 200 III 13C-triolein was dispensed on to the 
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same spoon and the rest of the mousse was eaten. The spoon was licked 
well and 50 mL water was drunk to wash the mousse down and rinse any 
residue from the mouth. Breath samples were collected every hour in 
duplicate for both isotopes. 10 mL of scintillation fluid, Emulsifier Safe was 
added to 14C samples and 14C levels counted on a scintillation counter in 
Vascular Medicine Department at Derbyshire Royal Infirmary. The samples 
contained within the Exetainers were tested in the Chemical Pathology 
Department at Derbyshire Royal Infirmary on the BreathMAT IRMS to give the 
13C02 : 12C02 ratios. The 14C results were calculated as in the 14C-triolein 
SOP (Appendix 11) and a report was sent to the consultant who had requested 
the test. Results for 13C-triolein breath test are presented as DOB, and 
cumulative DOB at 1-4 hours 4-6 hours and 1-6 hours, after ingestion of 
labelled triolein. 13C-triolein results were also expressed as peak percentage 
dose recovered (PDR) and cumulative PDR at 1-4 h, 4-6 hand 1-6 h post 
dose. Calculations for PDR for both isotopes included assumed CO2 
production rate of 9 mol/kg/h. 
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5 RESULTS 
5.1 MAINTAINING ANALYTICAL PERFORMANCE OF 13C02 
MEASUREMENT 
5.1.1 Zero enrichment (internal reproducibility) 
An example of a BreathMAT print out, after the pre set sequence "C02 zero 
20" has been run, is shown in Figure 5.1. The standard deviation of the 
Del13PDB values (with reference gas as baseline with Del13PDB - 29.00) 
was 0.054%0. 
Figure 5.1 - An example of a BreathMAT printout after the pre-set sequence 
"C02 zero 20" has been run. 
Ratio" No. Group No Olta of Acq 0.145 0.146 Rlti045 0.113 Del 13 POB mY 
1 1 2000111101-09:46: 0.06 -4.05 1.183823 0.420025 0.06 0.28,84 3254.3 
2 1 2000l11/0i-49:47: -4.01 -4.01 1.18379. 0.420089 . -4.01 -2i.01 3251.7 
3 1 2oo0/11/0i=09:48: 0.06 0.04 1.183885 0.420080 0.06 -2i.94 31D.8 
4 1 2000111/06-09:50: 0.01 -4.09 1.113867 0.420074· 0.;1 :D:3 .310.8 5 1 2000111/01-09:51: 0.12 0.03 1.1 3i13 0.420095 0.2 3 .2 
6 1 2000/11/01-09:52: 0.03 0.03 1.183915 0.420071 0.03 -28.'7 3252.1 
7 1 2000111/01-09:53: -4.06 0.04 1.183792 0.42011' -4.07 -2i.0I 3250.8 
8 1 2000/11/01-09:64: -4.02 0.00 1.183iOi 0.420088 -4.02 ~2i.02 3249.8 
9 1 2000/11/01-09:55: 0.02 0.01 1.183890 0.420107·· 0.02 -21 •• 1 3241.8 
10 1 2000111/08-09:56: -0.07 0.05 1.183i2i 0.420107 -4.08 .B.of 314i.2 
11 1 2000/11/06-09:57: 0.06 0.01 1.183i1l 0.420097 0.07 -2i.t5 3uh 
12 1 2000/11/06-09:56: 0.07 0.03 1.183i65 . 0.420095 0.07 -21 •• 5 324f.3 
13 1 2000/11/01-09:59: -4.01 0.08 1.183i07 0.420141 -4.02 -2i.02 3241.2 
14 1 2000111108-10:00: 0.04 -4.13 1.183135 0.420094 0.04 -21.iS 3ub 
15 1 2000/11/08-10:01 : -0.05 0.02 1.1838 •• 0.d0111 .-4.08 -H.05 3243.3 
16 1 2000/11106·10:02: 0.02 0.02 1.183967 0.420102 0.02 -21.8. 3Mb 
17 1 2000/1 f/08-1 0:03: -4.05 0.01 1.183i08 0.420138 -4.08 -21.05 3UU 
18 1 2000/11/01-10:04: .01 0.12 .183 57 0.420157 O. 1 34.4 
19 1 2000/11/0 10: 5: 0.02 -4.09 .183 47 0.420117 0.02 342.1 
20 1 2000111/08-10:06: 0.05 -4.03 1.183it5 0.420131 0.05 3241.8 
21 1 2000111/08-10:07:. 0.08 -4.02 1.1i4ooi 0.420140 0.08 323i.4 
22 1 2000111/08·10:08:· -4.05 0.03 . 1.184006 0.420141 . -4.08 3240.5 
5.1.2 Use of linearity correction 
Figure 5.2 shows the relationship between C02 concentration (as mV) and 
apparent Del13PDB with and without the use of "linearity" correction software. 
The figure shows that the linearity correction software corrects the results so 
that Del13PDB is independent of carbon dioxide concentration over a wider 
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range of carbon dioxide concentrations. Table 5.1 shows the effect of using 
the linearity correction software on precision of Del13PDB on another 
occasion when the same sample was analysed over a wide range of CO2 
concentrations. Linearity correction software was used for all subsequent 
analyses, except for those in Section 5.3. 
Table 5.1 - The effect of linearity correction on precision of Del13PDB 
mVRANGE Oel13 POB(%o) 
Mean SO 
Without linearity 623-1593 -25.11 0.40 
correction 
With linearity 564-1416 -25.89 0.08 
correction 
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Figure 5.2 The relationship between CO2 concentration (mV) and the apparent DeI13PDB, without 
and with the use of "linearity" correction. 
-+- Without linearity correction --With linearity correction 
/ ---~ 
/ ~ 
/~ ----. 
-----( 
J 
J 
200 400 600 800 1000 1200 1400 1600 
Total C02 concentration (expressed on BreathMAT as millivolts [mV)) 
51 
1800 
5.1.3 Precision of breath measurements 
Table 5.2 shows the results (OeI13POB and mV) for 10 replicates of the same 
breath sample. The mean of the Oel13POB results was -25.29 (SO = 0.12, 
CV = 0.47%). 
Table 5.2 - Precision of breath measurement 
SAMPLE NUMBER Del13PDB mV 
1 -25.44 3036 
2 -25.34 2821 
3 -25.20 2683 
4 -25.12 2713 
5 -25.23 2244 
6 -25.35 2841 
7 -25.27 2848 
8 -25.15 2749 
9 -25.31 2829 
10 -25.49 3077 
5.1.4 Between day analytical precision 
Table 5.3 shows the Oel13POB values for pairs of breath samples from the 
operator over 20 days. The mean difference was 0.0025%0 (SO = 0.14%0). 
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Table 5.3 - Reproducibility of Del13PDB values for pairs of breath samples 
from the operator over 20 days. 
DAY SAMPLE 1 SAMPLE 2 DIFFERENCE DeI13PDB%0 DeI13PDB%0 (DaB %o) 
1 -23.67 -23.71 -0.04 
2 -25.91 -25.89 0.02 
3 -26.35 -26.5 -0.15 
4 -25.53 -25.3 0.23 
5 -26.18 -26.37 -0.19 
6 -26.24 -26.27 -0.03 
7 -26.02 -26.08 -0.06 
8 -26.45 -26.35 0.10 
9 -25.58 -25.41 0.17 
10 -25.80 -25.89 -0.09 
11 -26.16 -26.32 -0.16 
12 -26.63 -26.36 0.27 
13 -24.47 -25.39 0.08 
14 -23.91 -23.89 0.02 
15 -24.45 -24.74 -0.29 
16 -25.08 -24.94 0.14 
17 -26.76 -26.80 -0.04 
18 -26.93 -27.00 -0.07 
19 -27.14 -27.10 0.04 
20 -27.14 -27.04 0.10 
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Table 5.4 shows the DaB for pairs of patient breath samples enriched with 
13C02. These were tested with 5 consecutive batches of patient samples on 
different days confirming acceptable precision over a wide range of carbon 
dioxide concentrations. 
Table 5.4 - Between day analytical precision for DaB (%0) for 2 pairs of patient 
samples re-tested in 5 batches of samples 
RE-TESTS PATIENT 1 PATIENT 2 
1 1.13 10.59 
2 1.28 10.48 
3 1.09 11.49 
4 1.12 11.18 
5 1.21 11.46 
Mean 1.17 11.04 
SD 0.08 0.48 
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5.2 ASSESSMENT OF THE PRECISION OF DISPENSING 200 f.1l OF 
OLIVE Oil 
Olive oil was used for this assessment as it has similar properties to 13C_ 
triolein. The plastic pipette tip was reduced by 1 cm to ease the flow caused 
by the viscous nature of the olive oil. The reverse pipetting technique was 
used to ensure accuracy; the oil was dispensed to the first pipette "stop", after 
which the pipette was held vertically for 10 seconds and the oil then 
dispensed again three times. This was repeated 10 times from the same olive 
oil sample with a new pipette tip each time. 
Table 5.5 shows the weight of olive oil when 200 f.1l aliquots were pi petted ten 
times. The mean weight was 0.1847 9 (SO = 0.0027 g, CV = 1.46%). 
Table 5.5 - Assessment of precision of dispensing olive oil. The weight (g) of 
olive oil of ten 200 f.1l aliquots is recorded. 
1 0.1890 9 6 0.1857g 
2 0.1857 9 7 0.1855 9 
3 0.1841 9 8 0.1820 9 
4 0.1859 9 9 0.1787 9 
5 0.1848 9 10 0.1854 9 
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5.3 BREATH 13C02:12C02 RATIOS: NATURAL VARIATION OVER 
ONE DAY 
In a healthy volunteer, after fasting overnight, the breath sample Del13PDB 
value was -24.33. The volunteer noted all food ingested and activities 
undertaken over the course of the day, as shown in Table 5.6. Breath 
samples were collected in duplicate at intervals throughout the day. DOB 
values varied from -1.97%0 to +0.5%0, relative to sample number 1, (Figure 
5.3). 
The data demonstrates the effect on precision due to variations in CO2 
concentrations between duplicates when linearity correction software is not 
used. Table 5.7 shows the variation in Del13PDB values between the 
duplicates. The difference in Del13PDB between duplicate breath samples 
varied from -0.51%0 to 0.36%0 (mean difference -0.057%0). The differences in 
total C02 concentration (expressed as mV) between the duplicates varied 
from 47 to 777 mV. Table 5.8a and 5.8b demonstrates that precision 
improves when the variation between CO2 concentration in duplicates is low. 
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Figure 5.3 Variation of OOB over one day 
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Table 5.6 - The variation of Del13PDB and DOB over one day in a healthy volunteer (V1) 
SAMPLE No TIME FROM TIME AVERAGE VALUE RELA T/vE FOOD ACTIVITY 
START Del13PDB TO BASELINE 
VALUES SAMPLE (DOB 0/00) 
1 0 0645 -24.33 0 Awoke 
2 0.75 0730 -24.37 -0.04 
3 1.25 0800 -25.02 -0 .69 Changing bed 
4 2 0845 -25.09 -0.76 Granary bread/tea/marm ite/marmalade 
5 2.25 0900 -25.23 -0.9 Washed teeth 
6 2.75 0930 -25.62 -1 .29 At work 
7 3.25 1000 -25.43 -1 .1 At work 
8 3.75 10.30 -25.34 -1.01 At work 
9 4.25 1100 -25.65 -1.32 Banana/coffee At work 
10 4 .75 1130 -25.45 -1 .12 At work 
11 5.25 1200 -25.59 -1 .26 At work 
12 5.75 1230 -25.69 -1 .36 At work 
13 6.25 1300 -26.30 -1.97 At work 
14 6.75 1330 -26.21 -1.88 Driving/shopping 
15 7.25 1400 -25.77 -1.44 Granary bread/cheese/pork pie 
mustard/tea/lime cordial/choc 
16 7.75 1430 -25.99 -1 .66 
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Table 5.6 (continued) - The variation of Del13PDB and DOB over one day in a healthy volunteer (V1) 
SAMPLE No TIME FROM TIME AVERAGE VALUE RELA TlVE FOOD ACTIVITY 
START Del 13POB TO BASELINE 
VALUES SAMPLE (OOB %o) 
17 8.25 1500 -25.99 -1 .66 Shopping 
18 8.75 1530 -24.67 -0.34 Wrapping presents 
19 9.25 1600 -24.64 -0.31 Tea Wrapping presents 
20 9.75 1630 -24.55 -0.22 Wrapping presents 
21 10.25 1700 -24.46 -0.13 Wrapping presents 
22 10.75 1730 -24.47 -0.1 Reading 
23 11 .25 1800 -23.83 0.5 Baked beans/toast/sausages lime cordiallbioyoghurtlchoc 
24 11.75 1830 -23.95 0.38 
25 12.25 1900 -24.66 -0.33 
26 12.75 1930 -24.21 0.12 Ironing 
27 13.25 2000 -24.16 0.17 
28 13.75 2030 -24.30 0.03 Coffee/milkl2 apples 
29 14.25 2100 -24.21 0.12 
30 14.75 2130 -24.36 -0.03 Ice cream/choc sauce 
31 15.25 2200 -24.73 -0.4 To bed 
32 20.75 0330 -25.17 -0 .83 Bathroom 
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Table 5.7 - The difference in Del13PDB and total C02 concentration (mV) 
values between duplicate samples over one day in a healthy volunteer (V1 , 
*this value is expressed as the modulus). 
DeI13PDB%o mV* 
SAMPLE 1 SAMPLE 2 SAMPLE 1-SAMPLE 2 SAMPLE 1-SAMPLE 2 
-24.14 -24.51 -0.37 394 
-24.23 -24.50 -0.27 192 
-24.98 -25.06 -0.08 67 
-25.04 -25.13 -0.09 222 
-25.19 -25.26 -0.07 125 
-25.65 -25.59 0.06 103 
-25.33 -25.52 -0.19 114 
-25.42 -25.25 0.17 95 
-25.65 -25.78 -0.13 224 
-25.30 -25.6 -0.3 211 
-25.4 -25.78 -0.38 402 
-25.76 -25.61 0.15 307 
-26.41 -26.19 0.22 229 
-25.95 -26.46 -0.51 601 
-25.61 -25.93 -0.32 518 
-25.96 -26.02 -0.06 374 
-25.9 -26.08 -0.18 85 
-24.67 -24.67 0 58 
-24.61 -24.66 -0.05 111 
-24.5 -24.59 -0.09 131 
-24.49 -24.43 0.06 20 
-24.61 -24.33 0.28 254 
-24.01 -23.65 0.36 777 
-23.82 -24.07 -0.25 255 
-24.45 -24.21 0.24 224 
-24.28 -24.13 0.15 145 
-24.09 -24.23 -0.12 47 
-24.22 -24.38 -0.16 162 
-24.16 -24.26 -0.1 107 
-24.36 -24.36 0 101 
-24.75 -24.71 0.04 71 
-25.26 -25.08 0.18 426 
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Table 5.8a - Variation in SD (of results shown in Table 5.7) due to non 
linearity of BreathMAT. 
DIFFERENCES IN mV BETWEEN DUPLlCA TES 
0-200 mV 0-300 mV 0-400 mV 0-500mV 0-800 mV 
Mean -0.049 -0.036 -0.042 -0.046 -0.057 
SO 0.121 0.162 0.169 0.181 0.21 
n 17 24 27 29 32 
Table 5.8b - Variation in SD, showing that precision improves when the 
variation between CO2 concentrations in duplicates is low. 
DIFFERENCES IN mV BETWEEN 
DUPLICATES 
0-200 mV 200-400mV 300-800 mV 
Mean -0.049 -0.031 -0.119 
SO 0.121 0.239 0.321 
n 17 10 8 
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5.4 BREATH 13C02:12C02 RATIOS; CHANGES AFTER INGESTING 
VARIOUS TEST MEALS TO AID ISOTOPE DELIVERY 
The properties of potential test meals, which could be used to aid isotope 
delivery to the small bowel, are shown in Table 5.9. On the basis of the data, 
it was decided to assess changes in breath 13C02: 12C02 ratios after ingesting 
Chunky Kit Kat, Scandishake, Duobar and lemon mousse. 
Table 5.9 - Foods assessed for suitability as a test meal (foods in bold are 
those tested in vivo) 
FOOD MADE BY WT ENERGY PROTEIN CARBOHYDRA TE FAT 
(g) (kJ) 9 (%) g(%) g(%) 
Lemon ORI 73 1.4 (4.6%) 10 (33%) 19.3 (63%) 
mousse 
Mars Mars, UK 65 1302 2.9 (5%) 47.8 (74%) 11 .9 (19%) 
Fudge choc Cadburys 24.5 480 0.7 (4%) 18.4 (75%) 4 .2 (17%) 
Twix Mars, UK 58 1203 2.7 (5%) 37.6 (65%) 11 (24%) 
Crunchie Cadburys 39 825 1.8 (5%) 30.3 (78%) 7.6 (20%) 
Milk choc McVities 366 1.2 
biscuit 
Organic fruiV Shepherdboy 50 919 8.4 (17%) 20.4(41%) 11.6 (23%) 
nut bar Ltd 
Full fat milk Natural 11.4 264 3.2 (28%) 4.7 (41%) 3.5 (34%) 
Penguin McVities 25.5 572 1.4 (5%) 16.4 (64%) 7 .3 (28%) 
biscuit 
Scandishake Nutricia 83 1831 4 (4.8%) 58 (70%) 21(25%) 
SHS 
Chunky Kitkat Nestle 55 1181 3.8 (7%) 32.9 (59%) 15.2 (27%) 
Ouobar Nutricia 45 1212 <1 22.4 (50%) 22.4 (50%) 
SHS 
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The 13C02: 12C02 ratios, expressed as DOB, following ingestion of the four 
test meals by a single subject (V1) on 4 separate days are shown in Figure 
5.4. The same activities were performed over the test period on each 
occasion. The result in Figure 5.4 shows marked differences in DOB 
responses following ingestion of the different test meals. 
Breath samples were collected from 4 patients, routinely referred for the 14C_ 
triolein fat absorption test, after ingestion of lemon mousse to confirm the 
isotopic neutrality of this test meal. However, unlike the volunteer, these 
patients had been allowed to have a light snack after the fourth hourly breath 
collection. Of these four patients, 3 were male and 1 female, their ages 
ranged from 36 to 65. Other variations in their profiles can be seen in Table 
5.10. The results from two additional patients were excluded due their BMI 
being greater than 29. 
Table 5.10 - Profiles of patients ingesting lemon mousse 
CODE SEX AGE WT(kg) HT (m) BSA (m2) BMI 
A M 59 79 1.86 1.88 22.8 
B M 59 80 1.83 1.86 23.9 
C M 65 58 1.85 1.62 16.9 
D F 36 60 1.65 1.55 22.1 
Range 36-65 58-80 1.65-1.86 1.55-1.88 16.9-23.9 
Mean 55 69 1.80 1.73 21.4 
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Figure 5.4 Changes in DOB (%0) with time after ingestion of4 test meals by a single subject (V1) 
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The results from the four patients are shown in Table 5.11 and confirm little 
change in DOB following ingestion of lemon mousse. The results from the 
volunteer who ingested the four meals and the mean of the four patients who 
ingested lemon mousse are shown in Table 5.12. 
Table 5.11 - Changes in DOB (%0) with time in four patients following ingestion 
of lemon mousse, without 13C-triolein. 
CHANGE IN DaB (%0) WITH TIME AFTER INGESTION OF 
LEMON MOUSSE 
PA TIENT CODE 1h 2h 3h 4h 5h 6h 
A 0.11 0.42 0.06 -0.26 -0.16 0.56 
B 0.3 0.21 0.27 0.41 0.05 0.09 
C -0.04 0.11 0.07 -0.02 0.08 -0.2 
D 0 0.31 0.22 -0.2 -0.45 -0.44 
Mean 0.09 0.26 0.16 -0.02 -0.12 0 
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Table 5.12 - DOB (%0) following ingestion of 4 test meals by a volunteer. The mean DOB for 4 patients following ingestion of lemon 
mousse is shown for comparison (data shown in Table 5.11). 
CHANGE IN DOB (roo) WITH TIME AFTER INGESTION OF TEST MEAL 
TEST MEAL SUBJECT 1h 2h 3h 4h 5h 6h 
Scandishake Volunteer V1 0.4 2.34 1.52 0.67 0.43 0.12 
Kit Kat Volunteer V1 -0.27 0.03 -0.59 -0.84 -0.07 -0.02 
Duobar Volunteer V1 -0.33 -0.33 -0.28 -0.84 -1.13 -1.19 
Lemon mousse Volunteer V1 -0.08 -0.32 -0.07 -0.5 -0.62 -0.9 
Lemon mousse Mean of 4 patients 0.09 0.26 0.16 -0.02 -0.12 0 
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5.5 BREATH 13C02:12C02 RATIOS; CHANGES AFTER INGESTING 
200 III 13C-TRIOLEIN WITH LEMON MOUSSE OR SCANDISHAKE 
The Del13PDB values were measured and DOB calculated over a 6 hour 
period in 2 healthy volunteers who ingested 200 J.ll 13C-triolein added to 
lemon mousse. Table 5.13 shows the DOB values after ingesting lemon 
mousse with and without 13C-triolein as the substrate. 
Table 5.13 - Comparison of DOB (%0) in two volunteers 1-6 h after ingesting 
200 III 13C-triolein and lemon mousse 
DOB (%0) WITH TIME AFTER INGESTING 
13C_ TRIOLEIN AND LEMON MOUSSE 
SUBJECT 1h 2h 3h 4h 5h 6h 
V1 1.80 6.07 6.78 6.73 5.86 5.21 
V19 1.71 3.1 5.07 6.71 8.14 6.74 
The results, compared with the changes observed in 4 patients who ingested 
lemon mousse without 13C-triolein (data from Table 5.11), are shown in Figure 
5.5. The peak DOBs following ingestion of 13C-triolein and lemon mousse 
were +6.8 and +8.2%0 compared to changes of -0.5 to +0.6%0 in the patients 
ingesting lemon mousse alone. 
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Figure 5.5 Changes in DOB (%0) in two volunteers (V1 and V19) who ingested 13C-tliolein and lemon 
mousse, compared to the changes in 4 patients (A,B,C and D) who ingested lemon mousse with no 
13C-tliolein. 
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In order to directly compare lemon mousse and Scandishake as potential 
carriers for the isotope in the fat absorption test, one volunteer (V1) ingested 
Scandishake with and without the addition of 13C-triolein (200 !J.L) and lemon 
mousse, with and without the addition of 13C-triolein (200 !J.L). The DOB 
values are shown in Table 5.14. Table 5.14 and Figure 5.6 also show the 
DOB expressed as the difference between test meal + 13C-triolein and the test 
meal alone. Although the DOB at 6 h was identical for the 2 test meals, the 
shapes of the response curves are very different. 
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Table 5.14 - Changes in DOB (%0) in a single volunteer (V1) for 0.5 h-6 h after separately ingesting lemon mousse and 
Scandishake with and without the addition of 13C-triolein (200 Ill). 
CHANGES IN DOB (%0) WITH TIME (h) AFTER INGESTING TEST MEAL ALONE AND WITH 13C _ TRIOLEIN 
TIME (h) LEMON MOUSSE LEMON MOUSSE +13C DIFFERENCE SCANDISHAKE SCANDISHAKE +13C DIFFERENCE 
0 0 0 0 0 
0.5 -0.27 0.9 1.17 -0.02 0.09 0.11 
1 -0.08 1.8 1.88 0.4 1.03 0.9 
1.5 -0.18 4 4.18 2.23 1.98 0.25 
2 -0.32 6.07 6.39 2.34 2.7 0.36 
2.5 -0.29 6.35 6.64 2.12 2.84 0.72 
3 -0.07 6.78 6.85 1.52 3.38 1.86 
3.5 -0.34 6.75 7.09 1.27 3.8 2.53 
4 -0.5 6.73 7.23 0.67 3.99 3.32 
4.5 -0.49 5.86 6.35 0.55 4.17 3.62 
5 -0.62 5.86 6.48 0.43 5.28 4.85 
5.5 -0.43 5.4 5.83 0.17 5.83 5.66 
6 -0.9 5.21 6.11 0.12 6.18 6.06 
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Figure 5.6 Changes in 008(%0) expressed as difference between ingestion oftest meal plus 13C-
triolein and the test meal alone for lemon mousse and Scandishake in a single volunteer (V1). 
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5.6 EVALUATION OF PROPOSED PROTOCOL FOR 13C-TRIOLEIN 
TEST OF FAT ABSORPTION 
5.6.1 Healthy volunteers 
The objective of this part of the study was to establish the normal range for 
the 13C-triolein test in healthy volunteers. The 18 subjects were all employed 
at the Derbyshire Royal Infirmary. 14 were from the Biochemistry Department, 
the remaining 4 were from the Vascular Medicine Department. Seven were 
male and 11 were female, their ages ranged from 22-61 years, with a mean of 
41. The details of subjects are shown in Table 5.15. 
Table 5.15 - Profiles of healthy volunteers 
SUBJECT SEX AGE (y) WT(kg) HT (m) BSA (m2) BMI 
V1 F 45 71 1.69 1.66 24.9 
V2 F 30 57 1.73 1.54 19.0 
V3 M 35 73 1.73 1.71 24.4 
V4 F 51 84 1.61 1.72 32.4 
V5 F 46 70 1.64 1.61 26.0 
V6 F 49 66 1.78 1.66 20.8 
V7 F 47 70 1.68 1.64 24.8 
V8 F 52 76 1.58 1.63 30.4 
V9 M 46 98 1.88 2.06 27.7 
V10 F 50 77 1.60 1.66 30.1 
V11 M 22 80 1.78 1.83 25.2 
V12 F 44 62 1.60 1.52 24.2 
V13 M 30 85 1.76 1.85 27.4 
V14 M 40 80 1.75 1.81 26.1 
V15 F 61 82 1.67 1.75 29.4 
V16 M 48 79 1.72 1.78 26.7 
V17 M 22 97 1.90 2.08 26.9 
V18 F 26 51 1.55 1.35 21.2 
Range 22-61 51-98 1.55-1.90 1.35-2.08 19.0-32.4 
Mean 41 75 1.70 1.71 26.0 
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The DOB values for the 18 subjects are shown in Table 5.16 for samples 
collected at 30 minute intervals over a 6 hour period, after ingesting the lemon 
mousse and 13C-triolein. 
Table 5.17 shows the peak DOB %0 and the cumulative (ie, sum of DOB %0 for 
hourly values) data for 1-4 hand 4-6 h with results uncorrected for BMI and 
corrected to a BMI of 25. In all cases, correction for BMI widened the 
standard deviation for the results. A wide variation in results was noted, for 
example, the peak DOB range was 1.0-7.4. The 3 lowest results were in 
subjects with BMI >29, and in general results in females were higher than in 
males. Table 5.18 therefore shows the data separately for males and females 
and excludes subjects with BMI >29. The t-test confirmed that results for men 
are lower than in women (p <0.05). The ranges for volunteer males and 
females expressed as mean ±2SD is shown in Table 5.19 (not corrected for 
BMI). 
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Table 5.16 - DOB (%0) in 18 volunteers 0.5-6 h after ingesting 13C-triolein and lemon mousse (figures in bold = peak values) 
DOB (0/00) IN VOLUNTEERS 0.5-6 h AFTER INGESTING 13C_ TRIOLEIN AND LEMON MOUSSE 
SUBJECT 0.5h 1.0 h 1.5 h 2.0 h 2.5 h 3.0h 3.5 h 4.0h 4.5h 5.0h 5.5 h 6.0 h 
V1 0.57 1.54 3.17 4.24 4.93 4.94 4.68 4.8 4.47 4.42 4.43 4.56 
V2 -0.13 0.20 0.45 0.93 1.63 3.39 4.56 6.44 6.39 6.77 5.47 5.39 
V3 0.8 1.29 1.20 1.32 1.47 1.33 1.78 2.07 1.63 2.06 3.34 3.54 
V4 -0.09 0.15 0.32 0.26 0.93 0.82 1.20 1.01 0.94 1.04 0.78 0.77 
V5 0.33 0.62 0.95 0.80 1.26 3.28 4.42 5.23 4.81 4.92 4.55 4.30 
V6 0.09 0.90 1.27 1.74 2.0 2.85 3.76 4.28 4.57 4.35 3.51 3.53 
V7 -0.05 0.25 2.19 2.33 3.16 5.08 5.91 6.08 5.96 4.76 4.69 3.97 
V8 0.40 0.58 0.42 0.64 0.32 0.37 0.96 1.34 1.90 2.20 2.48 2.48 
V9 0.20 0.54 1.08 1.27 1.73 1.88 2.22 2.89 3.37 2.70 3.64 3.57 
V10 0.14 0.75 1.00 1.50 2.03 2.54 3.45 4.06 4.61 5.08 4.94 4.77 
V11 0.02 0.10 0.34 0.40 0.56 0.99 1.38 2.41 3.13 4.28 4.71 4.50 
V12 0.40 0.87 2.79 3.76 5.57 6.17 7.21 7.42 7.50 7.31 6.87 6.18 
V13 -0.09 0.38 0.40 0.35 0.71 1.05 1.19 2.02 2.52 2.81 2.99 3.22 
V14 0.31 0.38 0.50 0.56 1.18 1.53 1.70 2.02 2.54 2.72 3.01 3.58 
V15 0 0.39 0.47 0.66 0.99 0.98 1.42 1.46 1.48 1.90 1.67 1.55 
V16 -0.06 0.56 1.05 1.35 2.06 3.17 3.69 3.77 3.42 2.88 2.39 2.66 
V17 0.56 0.59 0.75 1.06 1.38 1.25 0.88 1.68 2.39 3.07 2.63 2.57 
V18 0.38 0.60 2.04 2.54 3.41 3.58 3.06 4.69 5.33 4.86 4.12 4.57 
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Table 5.17 - DOB (%0) in 18 volunteers following ingestion of 13C-triolein and lemon mousse. Results are expressed as peak and 
cumulative DOB (%0) for 1-4 hand 4-6 h, with and without correction for BMI (corrected for BMI = observed DOB x 25/actual BMI) 
SUBJECT PEAK DOB%o PEAK DaB %0 
: 
CUMULA TIVE DaB (%0) CUMULA TIVE DaB (0/00) 
CORRECTED FOR BMI ,., ,.; 1-4 h CORRECTED FOR BMI 4-6 h CORRECTED FOR BMI 
V1 4.9 4.9 :/." 15.5 15.6 ,,- 13.8 13.9 
V2 6.8 8.9 11 .0 14.5 '.' 18.6 24.5 ,-.,C· 
V3 3.5 3.6 -(~~( 6.0 6.1 I -'~' .; 7.7 7.9 
V4 1.0 0.8 '::t3::" 2.2 1.7 . 2.8 2.2 
V5 5.2 5.0 ,_ '::i,- 9.9 9.5 I 14.5 13.9 
-
V6 4.4 5.3 I'; ;~c.,; 9.8 11 .8 .,. "," 12.2 14.7 
V7 6.1 6.1 1'-,' '. 13.7 13.8 .' 14.8 14.9 I " , 
V8 2.5 2.5 1':"/:', 2.9 2.4 -,~ 6.0 4.9 
V9 3.6 3.3 I ;;·::_~);. 6.6 6.0 ::',' " 9.2 8.3 
V10 5.1 4.2 I {:~c',} 8.9 7.4 ;5( 13.9 11 .5 
V11 4.5 4.5 1-- -:i;~_ 3.9 3.9 ;' "-.. ,' 11.2 11.1 
V12 7.4 7.6 I' I,,,,:; 18.2 18.8 ,~;, " 20.9 21.6 
V13 3.2 3.2 1::-;.:5,:" 3.8 3,5 : 
-
8.1 7.4 
V14 3.6 3.4 liJL::? 4.5 4.3 :!'-" 8.3 8.0 
V15 1.9 1.6 1:':::2;% 3.5 3.0 ;:~.': 4.9 4.2 
V16 3.8 3.5 k ;::H:'~' 8.9 8.3 ~J"- 9.3 8.7 
V17 3.1 2.9 I :~t;;~?i, 4.6 4.3 ;-~;; ; i 7.3 6.8 
V18 4.9 5.8 'i- ',; 11.4 13.4 :;:', 14.1 16.6 
Mean 4.19 4.28 1 i;,:W",:;· 8.07 8.24 ""'. 10.98 11 .17 
--
SO 1.64 2.00 :::,'. 4.64 5.22 , 4.76 5.91 
75 
Table 5.18 - DOB %0 in 14 volunteers (all with BMI <29) following ingestion of 13C-triolein and lemon mousse. Results are 
expressed as peak and cumulative DOB (%0) for 1-4 hand 4-6 h, with and without correction for BMI (corrected for BMI = observed 
DOB x 25/actual BMI) 
MALE 
SUBJECT PEAK DOB%o PEAK DaB 0/00 
.' CUMULA TIVE DaB {o/oo} CUMULA TlVE DaB (%o) 
CORRECTED FOR BMI : >- 1-4 h CORRECTED FOR BMI .'. :-' .' 4-6 h CORRECTED FOR BMI 
V3 3.5 3.6 ': ~.;. 6.0 6.1 [~? 7.7 7.9 
V9 3.6 3.3 S e 6.6 6.0 :<:., 9.2 8.3 
V11 4.7 4.5 3 3.9 3.9 :,,; .. 11 .2 11.1 
V13 3.2 3.2 f· ~ 3.8 3.5 " . 8.1 7.4 
V14 3.6 3.4 . -:::.,t 4.5 4.3 . .::--, 8.3 8.0 
V16 3.8 3.5 . o::~~:, 8.9 8.3 :/ 9.3 8.7 
V17 3.1 2.9 ,.{±:.r:~ 4.6 4.3 Sj,<~ 7.3 6.8 
Mean 3.6 3.5 ~~-::·.-'i~i 5.5 5.2 :~;~: :~ 8.7 8.3 
SO 0.5 0.5 ;-: 1.8 1.7 ' ..... 1.3 1.4 
FEMALE 
V1 4.9 4.9 .:: " 15.5 15.6 I :>,J 13.8 13.9 
V2 6.8 8.9 /t~~~~ 11 .0 14.5 (.t:n 18.6 24.5 
V5 5.2 5.0 .:~::~~( 9.9 9.5 I,;·t:-. ~. 14.5 13.9 
V6 4.4 5.3 ~'"1.i~:~ 9.8 11.8 1 1ft~:,,? 12.2 14.7 
V7 6.1 6.1 ;\~;:;,; 13.7 13.8 I ~~,<': 14.8 14.9 
V12 7.4 7.6 ·t·~~t'~: 18.2 18,8 I ;~'~\':~ 20.9 21 ,6 
V18 4.9 5,8 ./i:-jji 11.4 13.4 I ~\}f:'·: 14.1 16.6 
Mean 5.7 6.2 ':~;.:~i 12.8 13.9 I 'j~(>':' 15.6 17.2 
SO 1.1 1.5 ,'y; 3.2 2.9 .' .. :: 3.1 4.2 
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The reproducibility of the results was assessed in 2 volunteers (V1 and V3) by 
repeating the procedure after intervals of 6 months for V1 and 5 weeks for V3. 
Figure 5.7 shows the reproducibility of the results in the 2 volunteers. 
Table 5.19 - DaB (%0) expressed as mean ±2SD for males and females for 
peak, and 1-4 hand 4-6 h breath samples. 
PEAK 1-4 h 4-6 h 
(DaB %o) (DaB o/oo) (DaB o/oo) 
Male 2.6-4.6 1.9-9.1 6.1-11 .3 
Female 3.5-7.9 6.4-19.2 9.4-21.8 
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Figure 5.7 Change in DOB (%o) with time after ingestion of lemon mousse and 13C.triolein in two 
volunteers (V1 and V3) tested on two separate occassions. 
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5.6.2 Patients 
The objective of this part of the study was to compare results by the 14C_ 
triolein and 13C-triolein absorption tests using the proposed 13C-triolein 
protocol. 
Twenty six patients referred by the gastroenterologists for the 14C-triolein test 
agreed to simultaneously undertake the 13C-triolein test. 15 were male and 11 
were female, their ages ranged from 20 to 73 years with a mean of 47 years. 
Details of the patients are shown in Table 5.20. 
In order to evaluate the proposed protocol, the patients were classified into 
the following 4 groups on the basis of the diagnostic information available: 
Group 1 
Group 2 
Group 3 
Group 4 
Diagnosis consistent with normal fat absorption. 
Diagnosis consistent with fat malabsorption. 
Patients excluded because of other factors which 
may interfere with the test, for example, diabetes, 
BMI >29, or no clinical information available. 
No reason to exclude; but insufficient information to 
assign to Groups 1 or 2. 
The DOB %0 values for the 26 patients assigned to Groups 1, 2, 3 or 4 are 
shown in Table 5.21 for samples collected at 1 hour intervals over a 6 hour 
period following ingestion of the 13C-triolein. 
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Table 5.20 - Information on patients undergoing investigations for fat malabsorption. 
PATIENT SEX AGE (y) WT(kg) HT (m) BSA (m2) BMI 14C _ TRIOLEIN DIAGNOSIS 
1 M 73 86 1.72 1.84 29.1 4.5 Diabetes, jejunal diverticulosis 
2 M 61 84 1.78 1.96 26.5 4.1 ?Sile salt malabsorption 
3 M 33 86 1.8 1.9 26.5 3.1 No information available 
4 M 44 73 1.75 1.73 23.9 3.6 Pancreatic insufficiency, alcohol induced 
5 F 20 48 1.57 1.33 19.5 2.7 No diagnosis; probable fat malabsorption 
6 M 43 70 1.55 1.55 29.2 3.1 (With Creon); no info available 
7 M 55 73 1.65 1.65 26.8 4.9 Probable Irritable bowel syndrome(ISS) 
8 M 39 72 1.98 1.88 18.4 5.9 No information available 
9 M 54 79 1.8 1.83 24.4 4.5 Probable ISS 
10 F 33 71 1.57 1.58 28.9 5.0 Probable ISS 
11 M 39 70 1.67 1.65 25 4.7 Jogger's diarrhoea 
12 M 53 95 1.8 1.95 29.3 1.9 Probable ISS 
13 M 31 77 1.78 1.79 24.3 2.5 No information available 
14 F 36 76 1.65 1.69 27.9 3.5 Lactose intolerance 
15 M 48 80 1.83 1.85 23.9 2.6 Diabetes, partial villous atrophy, lactose 
intolerance, no final diagnosis 
16 F 56 63 1.57 1.5 25.6 3.4 Probable ISS 
17 F 57 61 1.57 1.48 25.6 2.1 No diagnosis; probable fat malabsorption 
18 F 68 61 1.57 1.48 25.6 4.5 ISS 
19 M 56 56 1.65 1.47 20.6 1.1 Coeliac disease; fat malabsorption 
20 F 23 82 1.57 1.68 33.3 3.2 Probable ISS 
21 F 29 45 1.4 1.2 22.9 1.7 Coeliac disease; fat malabsorption 
22 M 45 89 1.72 1.85 30.1 4.8 No diagnosis 
23 F 66 90 1.7 1.85 31.1 3.3 Diabetes; metformin induced diarrhoea 
24 F 39 50 1.65 1.4 18.5 3.5 Chronic pancreatitis (alcohol induced) 
25 F 64 68 1.6 1.53 26.6 1.3 Coeliac disease; pancreatic insufficiency 
26 M 65 55 1.7 1.49 19 2.4 Coeliac disease; untreated 
Range 20-73 45-95 1.40-1.98 1.20-1.96 18.4-3.33 
Mean 47 72 1.68 1.66 25.50 
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The 13C-triolein results are also expressed as the cumulative DOB %0 for 1-4 
hours, 4-6 hours and 1-6 hours and compared with 14C-triolein expressed as 
peak CO2 excretion/hour as % of dose given. The results for the patients in 
Groups 1 and 2 are shown graphically in Figure 5.8 and show that overall 
DOB values are lower in those patients with fat malabsorption (Group 2). The 
mean for the cumulative DOB values for Groups 1 and 2 were compared by 
the t-test. The results shown in Table 5.22 demonstrate that the results for 
Group 2 are significantly lower than Group 1. Patients in Groups 3 and 4 
were not evaluated further but the results are shown in Figure 5.9. 
Correlation coefficients for the 13C-triolein breath test (expressed as 13C DOB 
and 13C percentage dose recovered (PDR)) compared with 14C-results 
expressed as peak 14C PDR were as follows: 
13C (oOB) vs peak 14C PoR 13C (POR) vs peak 14C POR 
All patients Groups 1 & 2 All patients Groups 1 & 2 
At peak 0.50 0.56 0.59 0.72 
Cum 1-4 h 0.26 0.61 0.25 0.63 
Cum 4-6 h 0.49 0.62 0.57 0.68 
Cum 1-6 h 0.43 0.65 0.45 0.70 
The PDR comparisons for peak, 1-4 hand 4-6 h are shown in Figures 10a, 
10b and 10c for Groups 1 and 2. 
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Table 5.21 a - 13C-triolein breath test results for 26 patients assigned to 
diagnostic groups. (Group 1: Diagnosis consistent with normal fat absorption, 
Group 2: Diagnosis consistent with fat malabsorption, Group 3: Patients 
excluded because of diabetes, BMI >29 or no clinical information available, 
Group 4: No reason to exclude; but insufficient information to assign to 
Groups 1 or 2). 
DOB (%0) HOURS POST DOSE CUMULA TlVE DOB 
(%0) 
Patient 1 2 3 4 5 6 1-4 h 4-6 h 1-6 h 
Group 1 7 0.51 1.19 2.02 2.42 3.58 4.09 6.14 10.09 13.81 
9 0.46 0.87 2.04 4 3.78 3.56 7.37 11.34 14.71 
10 0 0.45 2.39 3.01 3.42 5.07 5.85 11.50 14.34 
11 0.57 1.54 2.85 4.83 6.15 5.51 9.79 16.49 21.45 
14 0.62 1.33 1.05 2.98 3.74 4.34 5.98 11 .06 14.06 
16 0.42 0.52 1.2 3.73 6.69 5.89 5.87 16.31 18.45 
18 0.30 0.80 1.13 1.20 2.56 4 .38 3.43 8.14 10.37 
Group 2 4 0.74 1.01 1.45 1.76 1.86 0.23 4.96 3.85 7.05 
5 -0.99 0.02 0.32 1.52 2.03 0.55 0.87 4.10 3.45 
17 -0.53 0.54 1.85 2.02 1.65 1.09 3.88 4.76 6.62 
19 0.57 1.17 1.76 1.68 2.66 2.79 5.18 7.13 10.63 
21 -0 .51 0.27 1.08 2.47 1.94 1.05 3.31 5.46 6.30 
25 0.44 0.46 0.24 0.93 1.44 2.21 2.07 4.58 5.72 
26 0.11 0.40 1.13 1.74 1.26 1.66 3.38 4.66 6.30 
Group 3 1 -0 .04 0.18 0.41 1.33 2.03 3.01 1.88 6.37 6.92 
3 0.16 0.22 0.67 1.03 1.82 3.45 2.08 6.30 7.35 
6 -0 .67 -0.54 -0 .65 -0.55 2.32 3.61 -2.41 5.38 3.52 
8 0.44 1.3 2.26 3.47 4.09 5.32 7.47 12.88 16.88 
12 0.45 1 1.88 1.42 1.7 3.39 4.75 6.51 9.84 
13 1.29 1.99 2.91 3.64 4.08 4.27 9.83 11 .99 18.18 
15 -0 .08 0.09 0.68 0.98 0.65 0.51 1.67 2.14 2.83 
20 0.52 0.54 0.24 0.63 2.61 3.91 1.93 7.15 8.45 
22 -0.12 0.24 0.94 0.98 2.34 3.51 2.04 6.83 7.89 
23 -0.09 -0.12 -0.63 0.3 1.19 2.3 -0 .54 3.79 2.95 
Group 4 2 0.1 0.11 0.6 1.25 2.13 2.44 2.06 5.82 6.63 
24 0.25 0.25 1.49 3.27 5.09 4 .37 5.26 12.73 14.72 
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Table 5.21 b - Peak % dose recovered for 13C and 14C-triolein breath tests 
and cumulative % dose recovered for 13C-triolein for 26 patients assigned to 
diagnostic groups (as Table 5.21 a). 
PEAK % DOSE CUMULATIVE 
RECOVERED PERCENTAGE DOSE 
RECOVERED 
Patient 13C-triolein 14 C-triolein 1-4 h 4-6 h 1-6 h 
Group 1 7 4.83 4.9 5.79 8.06 13.86 
9 5.11 4.5 6.86 9.65 16.51 
10 5.82 5.0 4.99 8.56 13.55 
11 6 .96 4 .7 8.34 12.81 21.15 
14 5.33 3.5 5.52 9.09 14.61 
16 6.81 3.4 4.10 11 .71 15.81 
18 4.43 4.5 2.69 5.33 8.02 
Group 2 4 2.19 3.6 4.81 3.37 8.18 
5 1.57 2.7 0.05 2.38 2.43 
17 3.23 2.1 4.24 3.16 7.40 
19 2.53 1.1 3.93 4.43 8.36 
21 1.80 1.7 1.51 2.69 4.20 
25 2.43 1.3 1.76 3.31 5.07 
26 1.55 2.4 2.23 2.63 4.86 
Group 3 1 4.18 4.5 1.69 5.84 7.53 
3 4.80 3.1 2.18 5.64 7.82 
6 4.08 3.1 -1 .28 5.49 4.20 
8 6.19 5.9 6.67 9.87 16.55 
12 5.21 1.9 6.36 6.46 12.81 
13 5.31 2.5 9.97 10.00 19.97 
15 1.27 2.6 1.51 1.80 3.32 
20 5.18 3.2 2.14 6.47 8.61 
22 5.05 4.8 2.22 6.58 8.80 
23 3.35 3.3 -1 .0 3.62 2.62 
Group 4 2 3.31 4.1 1.95 5.40 7.35 
24 4.11 3.5 2.93 7.20 10.13 
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Table 5.22a - Comparison of cumulative DOB values for Groups 1 and 2 
CUMULA TlVE DOB, MEAN (AND SO) 
FOR TIME PERIODS SHOWN 
GROUP 1 GROUP 2 p-VALUE 
1-4 h 6.35 (1 .92) 3.38 (1 .53) 0.0042 
4-6 h 12.13 (3 .13) 4.93 (1 .10) 0.0004 
1-6 h 15.31 (3 .58) 6.58 (2.13) 0.0001 
Table 5.22b - Comparison of peak % dose recovered and cumulative 
percentage dose recovered 1-4 h, 4-6 hand 1-6 h in Groups 1 and 2. 
GROUP 1 GROUP 2 p-VALUE 
Peak 5.61 (0.97) 2.49 (0 .61) <0.001 
1-4 h 5.47 (1.83) 2.65 (1 .73) 0.0194 
4-6 h 9.32 (2.45) 3.14 (0 .68) <0.001 
1-6 h 14.79 (3 .93) 5.79 (2.24) 0.001 
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Figure 5.8 13C-triolein breath test results for Group 1 (normals fat absorption, solid lines) and Group 2 
(fat malabsorption, dotted lines) 
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Figure 5.9 13e-triolein breath test results for Group 3 (patients excluded from Groups 1 and 2) and 
Group 4 (insufficient information, patients 2 and 24) 
86 
c:: 
c 
c.. 
6 
5 
4 
i 3 
Cl) 
c.. 
U 
... 
... 
2 
o 
o 
Figure 6.10a Comparison Of 14C Peak PDR and 13C Peak PDR in Group 1 and Group 2 
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Figure 5.10b Comparison of 14C Peak PDR and 13C Cumulative 1-4h PDR in Group 1 and Group 2 
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Figure 5.10c Comparison Of 14C Peak PDR and 13C Cumulative 4-6h PDR in Group 1 and Group 2 
• Group 1 (normal fat absorption) • Group 2 (fat malabsorption) 
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6 DISCUSSION 
In Southern Derbyshire, which has a population of 500,000, 4,000 patients are 
referred annually to the Gastoenterology clinics at Derbyshire Royal Infirmary 
and Derby City General Hospital for further investigations. 5-10% of these 
patients will require tests for the assessment of small bowel disorders. In 
about 1 % of cases, a test for fat absorption forms a valuable part of the 
investigation as it covers a range of metabolic processes of digestion. 
In the Derby hospitals the test used since 1987 is the 14C-triolein breath test. 
The current study has set out to develop a 13C-based test for fat absorption as 
an alternative to 14C-triolein and which can be used routinely in an out patient 
department of any hospital. 
In the 13C breath tests as in the 14C breath tests, administration of labelled 
substrate results in the production and exhalation of labelled C02 as the 
substrate is oxidised. Unlike 14C tests in which the isotope background is low, 
13C tests are performed against a large background or natural abundance of 
1.1% 13C (32). 
The study investigated the effect of food, exercise, 13C dose and analytical 
precision of the BreathMAT during the development of the 13C-based test for 
fat absorption. 
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Effect of food 
The results shown in Figure 5.3 demonstrate the variation in DOB over the 
course of one day with measured Del13PDB values varying from -26.30 to 
-23.83%0. The changes are due both to the type of food ingested and the 
activities of the subject (Table 5.6). For a satisfactory 13C-breath test, the pre-
dose 13C enrichment of C02 in the breath should be low and stable, ie, foods 
that are abundant in 13C must be avoided, for example tuna or pineapple (44). 
A rice based diet has been used in some 13C-breath tests (32) as rice has a 
low 13C content. This is in contrast to foods containing maize and cane 
sugars that contain high levels of 13C (44). Rice gives a value of -24 
(expressed as the difference from the PDB standard per mil) which is similar 
to values typically found in subjects on a European diet. By contrast, maize 
flour has a value of -10. North Americans typically have breath 13C02 values 
of -22 reflecting the higher amounts of maize, and cane sugar, in their diets. 
Patient preparation prior to the test is therefore very important. The patients 
in this study were required to fast from the midnight before the morning of the 
test although they could have a cup of tea before the test and a light lunch 4 
hours after beginning the test. Discrimination between normal fat absorbers 
and fat malabsorbers might be improved if dietary restrictions were imposed 
for the last meal on the evening prior to the test date. For example, patient 
preparation for the breath hydrogen test requires that nothing to be eaten from 
7.00 pm until the test has finished the following morning, but drinks may be 
consumed. In the last meal before 7.00 pm, the patient must not eat beans, 
bread, pasta or any other food containing wheat flour. Imposing these 
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restrictions has not lead to any problems with the acceptability of that test to 
patients at the Derbyshire Royal Infirmary. 
In the context of fat absorption tests, Schoeller et al. (47) showed that a 
patient who had fasted overnight before a breath test would have been 
producing C02 mostly from fatty acid oxidation whereas subjects who had 
ingested a meal containing carbohydrates and proteins would have a greater 
abundance of 13C02 in breath. Loser et al. (48) mentioned that his subjects 
fasted for 12 hours overnight before evaluation of the 13C mixed triglyceride 
breath test, but did not indicate any additional dietary restrictions. 
In the present study, various foods were investigated as possible meals in the 
fat test. All those selected had similar amounts of fat (Table 5.9) and fulfilled 
our requirement for a test meal to contain about 20 g fat. Lemon mousse 
showed the least change in 13C values from baseline over 6 hours, with the 
mean change in DOB 1-6 hour after ingestion varying from only -0.12 to 
+0.26%0 in 4 subjects (Table 5.10 and 5.11). Figure 5.4 compares the other 
three test meals (Scandishake, Duobar and Kitkat) with lemon mousse in a 
single subject (Table 5.12). The shape of the response after ingesting 
Scandishake is distinct from the other meals in that the DOB values rises to 
2.3, two hours after the meal, whereas the other meals do not rise above 
zero. This difference is probably due to the larger amount of carbohydrate 
contained in the Scandishake, which is rapidly absorbed and metabolised 
after fasting. It also contains corn syrup solids which will lead to enrichment 
of breath 13C02. The sugar used in the recipe for the lemon mousse is refined 
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from sugar beet which has a low 13C level of -27%0 (44), and is probably the 
reason the DOB value does not rise above zero after ingesting lemon 
mousse. The lemon mousse thus most closely fulfils the requirement for an 
isotopically neutral test meal to be used as a carrier for the labelled substrate. 
During the procedure, we have been measuring the "change" from normal 
baseline values for that particular individual. It is important that the patient 
fasts before the test to give a stable baseline. Withholding food for 8 hours 
before and throughout the breath test eliminates or reduces the baseline shifts 
in 13C abundance (43). The volunteers did fast before and during the test 
(see Results 5.6), although the patients were allowed a light meal 4 hours 
after ingestion of the test meal as permitted in the 14C-triolein procedure. 
Turner et al. (14) showed significant discrimination between normal fat 
absorbers and fat malabsorbers when using 14C labelled triolein and patients 
ingesting a light meal after 4 hours. 
However, the 13C breath test is likely to be more sensitive to food ingestion. 
Table 5.11 shows the results of four patients after lemon mousse, no 13C_ 
triolein and a light lunch after 4 hours. There is little change in DOB over the 
6 hours. There are greater differences between patient's DOB at six hours 
than earlier in the test suggesting that the ingestion of food at 4 hours could 
have had a variable effect on breath 13C02. Figure 5.4 shows a trend towards 
a negative DOB in a volunteer who ingested lemon mousse but no lunch at 4 
hours; however, this volunteer did not rest during the period of the test. 
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The 14C triolein breath test protocol as described by Turner et al. (14) states 
~--
... ---
that the patient needs to fast from midnight on the night before the test, ie, for 
nine hours before the test. The experience of using this test in Derby has 
proved that this fasting regime is acceptable to patients. 
Effect of exercise 
Another factor to be taken into consideration is the activity of the patient 
before and during the test. Schoeller et al. (47) showed that mild exercise 
was found to increase the variations in 13C02 output. This variation is shown 
in the Results section 5.3 where the natural variation of 13C02: 12C02 ratios 
was observed over a day. Exercise will increase the percentage of CO2 
production in the muscle mass and increase the mobilisation of glycogen and 
change the percentage of carbohydrate, protein and lipid being oxidised to 
CO2. The increase in CO2 will dilute the labelled CO2 and so reduce the 
sensitivity of the test. The volunteers in the study were NHS employees who 
.. 
continued with their normal activities whereas the patients were relatively 
sedentary for the period of the test. This is an area which could be 
investigated further by assessing the length of time taken to reach a stable 
baseline after patients have travelled to the hospital on the morning of the test 
and by comparing changes in breath 13C02: 12C02 ratios in volunteers who 
rest completely after ingesting the lemon mousse with those who continue 
their normal activity. But at present the variation in the levels of exercise by 
both groups in the study means that the volunteer data could not be used to 
derive a reference range for this test of fat absorption. 
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Whether or not to measure rate of C02 production has been debated in many 
papers. Duncan et al. (17) states that assuming a uniform CO2 production 
rate can introduce errors. Amarri et al. (31) states that measuring CO2 
production rate is vitally important to ensure accurate calculation of PDR 
(percentage 13C02 dose recovered). Ling et al. recently used a ventilated 
hood indirect colorimeter to measure carbon dioxide production in a 13C-mixed 
triglyceride breath test in children (52). Vantrappen et al. (20) measured CO2 
and showed a difference in CO2 production rate between normal subjects and 
in patients with pancreatic disease. He quoted a simplified procedure which 
assumed a production rate of 300 mmol per unit body surface area per hour. 
Turner et al. (14) assumed the C02 production rate of 9 mollkg/h when 
developing their test for fat absorption which showed good discrimination 
between normal patients and fat malabsorbers. In the current study, 
instrumentation was not available to test C02 production levels so the rate of 
9 mollkg/h was assumed. Schoeller et al. (47) states that the SD of CO2 
production rates is less than 25% for resting adults and children, and 
concluded that the diagnostic value will not be significantly reduced if a C02 
production rate correction factor is not used as the responses of normal and 
diseased patients usually differ by a factor of 2. 
Effects of the type of fat source 
The type of labelled fat used for the test is important. Dietary triacylglycerols 
can be absorbed only after they have been hydrolysed by gastrointestinal 
lipases to give fatty acids and monoacylglycerols (4). In vivo, different 
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triacylglyeerols are hydrolysed at different rates. For example, triacylglycerols 
.... -: . 
.... 
that contain long chain, saturated fatty acids are hydrolysed more slowly (and 
therefore absorbed more slowly) than medium chain triglycerols (41). The site 
of absorption depends on the rate of absorption; triglycerides that are more 
slowly absorbed, for example those with long chain saw rated fatty acids, tend 
to have a more distal site of absorption. 
As described in the Introduction, triolein is considered to be the best substrate 
for assessment of all the processes of fat absorption, ie, a "global 
assessment". Therefore, triolein, a long chain triglyceride, was used as the 
substrate in this study to evaluate the overall process of fat absorption. Using 
triolein as the labelled fat ensures a direct comparison with the existing 14C_ 
triolein test for fat absorption. 
Effect of 13C dose 
~ 
The ingestion of a sufficiently high dose of substrate is essential to ensure 
clear discrimination between normal and abnormal results but cost restricts 
the amount used. The dose of 200 ~L (185 ~g) of 13C-triolein costs about 
£40; a balance has to be struck between a large 13C-enrichment in breath 
CO2 and cost. The cost of 14C-triolein used currently at Derbyshire Royal 
Infirmary is £30, but there are also administration costs involved when using 
radiological materials. 
The accurate dispensing of the substrate was essential to ensure 
reproducibility between patients. The repetitive pipetting of olive oil using a 
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pipette tip with 1 cm removed gave a CV = 1.46% (Table 5.4). Thus the 
reproducibility of dispensing the dose was deemed to be acceptable for this 
study. 
The aim of this research has been to use a dose of 13C-triolein that will show 
an adequate response (enrichment), that is adequate production of 13C02 in 
exhaled breath in a normal working day. Then the test will be able to be 
performed at a single outpatient visit. 
It has been shown by Lembcke (32) that a dose of 2 mg/kg patient weight, ie, 
120 mg for an average 60 kg patient, is adequate for the 13C-hiolein breath 
test. Vantrappen et al. (20) used 240 mg 13C-mixed triglyceride for their fat 
absorption test. Loser et al. (48) used both 200 mg and 250 mg of 13C-mixed 
triglycerides as an indirect pancreatic function test. A trial dose of 200 J.!L of 
13C-triolein, equivalent to 185 J.!g, was used in the protocol and this proved to 
give an adequate response as shown in the Results (Figure 5.5, Table 5.13), 
with peak DOBs of 8.14 and 6.78 in 2 volunteers. Table 6.1 shows the 
comparison of peak %0 dose/hour recovered in normal subjects using different 
13C-labelled fats. It should be noted that the lower dose used and the higher 
percentage recovered by Lembcke is due to the use of hiolein, an algal 
product with uniformly 13C-labelled triglyceride (98%). The percentage dose 
recovered after the use of 13C-triolein compares favourably with previous 
research. 
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Table 6.1 - Comparison of peak %0 dose/hour recovered in normal subjects 
using different 13C-labelled fats. 
TEST DOSE PEAK 0/00 DOSE/HR IN AUTHOR NORMAL SUBJECTS 
13C-hiolein 120 mg 10%0 Lembcke (32) 
13C-mixed triglyceride 240 mg 8%0 Vantrappen (20) 
13C-mixed triglyceride 200mg 6%0 Loser (48) 
13C-triolein 185 mg 5%0 This study 
The quantity of fat in the test meal is important because gastric emptying will 
affect the rate at which the substrate leaves the stomach and is available for 
digestion in the small intestine. Gastric emptying is affected by the osmolality 
of the meal and a large fat meal will delay stomach emptying. 
In the Introduction, it was noted that the amount of fat present in test meals 
used to assess fat absorption ranged up to 60 g. Duncan et al. (16) state that 
20 g of fat is the optimum quantity, as too much fat in the test meal can delay 
gastric emptying. The four meals (Sandishake, Duobar, Kitkat and lemon 
mousse) were expressed as shown in Figure 5.4. Over the 6 hours, the test 
would be carried out, the response to Scandishake gave a DOB range from 0 
to 2.4, Kitkat gave a DOB response of 0 to -0.8, Duobar 0 to -1.2 and lemon 
mousse 0 to -0.8. 
Initial thoughts were that a commercial product could be used as the test 
meal. If a suitable product had been found the test could be performed more 
easily in any hospital and the samples returned to a central laboratory for 
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testing. :fable 6.2 shows the comparison of two Penguin biscuits bought at an 
..... 
interval of two months which shows the total weight has reduced, percentage 
of protein and fat decreases and an increase in carbohydrate. As can be 
seen, products can vary significantly over a short time span. Pharmaceutical 
products are likely to vary to a lesser extent due to tighter restrictions and 
regulations but no satisfactory product could be found. 
Table 6.2 - Comparison of composition (declared by the manufacturer) of 
Penguin biscuits A and B purchased over a 2 month period. 
A A (%) B B(%) 
Weight (g) 25.5 24.6 
Energy (kj) 572· 549 
Protein (g) 1.4 5.5 1.3 5.3 
Carbohydrate·s (g) 16.4 64.3 16.1 65.5 
Sugar (g) 10.3 10.1 
.. 
Fat (g) 7.3 28.6 6.8 27.6 
Saturates (g) 4.9 4.6 
Fibre (g) 0.4 1.6 0.4 1.6 
Sodium (g) <0.1 <0.1 
Therefore, lemon mousse was used in this study, as the recipe includes 20 g 
fat, it is isotopically neutral and is made locally in the Derbyshire Royal 
Infirmary Catering Department. 
To conclude, there are a number of factors which will affect the sensitivity of 
the test, ie, food ingested prior to the test, fat meal used, effect of exercise 
before the baseline sample taken, type and quantities of labelled fat. 
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Analytical quality 
In 1998, a European inter-laboratory comparison of breath 13C02 analysis was 
performed by Stellard and Geypens (49). This survey showed a large number 
of analytical variables (suppliers, models, inlet systems and procedures) but 
as long as each laboratory ensured regular calibration of the system and an 
standardised analytical procedure was used, the results obtained by the 
Finnegan BreathMAT were comparable with other IRMS analyses currently 
available. 
Acceptable analytical quality is essential to ensure confidence in the validity of 
the results produced and must be demonstrated over the time period of the 
study. The routine checks of analytical quality of the BreathMAT include 
multiple analysis of the same sample, ie, the reference gas. This is carried 
out as a preset analytical sequence and variability of the Oel13POB result 
reported. Acceptable precision is indicated by an SO of less than 0.1%0. 
Figure 5.1 gives an example of this sequence, with an SO of 0.054%0. Over 
the time of the study this gave consistently acceptable standard deviation 
values. Unlike the reference gas, breath samples have variable C02 
concentrations and Figure 5.2 and Table 5.1 demonstrate the importance of 
the linearity correction software in reducing the imprecision of Oel13POB 
measurements when CO2 concentration varies for the same breath sample. 
"Linearity" software enables the relationship between the CO2 concentration 
(as mV) and the apparent Oel13POB concentration to be independent of each 
other (Figure 5.1). The standard deviations improved significantly from 0.40%0 
to 0.08%0. Table 5.2 shows acceptable precision for Oel13POB (SO = 0.12%0) 
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when 1 CUeplicate breath samples from a volunteer were collected over a 
.... 
period of a few minutes in the manner described (section 4.2.1 b). 
All the results quoted in the study are expressed as the difference from the 
. 
base line Del13PDB value at a certain time after inge~ng the 13C substrate, 
ie, as DOB. The analytical detection limit is defined as the smallest value that 
can be distinguished from zero with a defined degree of confidence. For this 
study, it was therefore necessary to assess the precision of measuring DOB 
in order to determine what increase in DOB is significantly different from 
background DOB. Paired breath samples collected from the operator within a 
few seconds should have a DOB of zero. Table 5.3 shows the variability in 
DOB in samples collected in this way on 20 different days and therefore 
included any additional analytical variability due to "between day" factors such 
as temperature or variability in ion source. The mean difference from zero 
was +0.0025% with an SD of 0.14%0. In clinical biochemistry, the analytical 
.. 
detection limit is usually defined as zero plus 3SD, ie, a change in DOB of 
>0.42% represents a significant change from the baseline (50). 
The data collected over the course of one day by a volunteer (Table 5.6) 
shows the effect on precision due to variations in CO2 concentrations between 
duplicates when linearity correction software is not used (Table 5.7). Tables 
5.8a and 5.8b demonstrate that precision improves when the variation 
between CO2 concentrations in duplicates is low. This again shows the 
importance of using the linearity software program during the course of this 
study. 
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A protocol for monitoring analytical quality over the period of this study has 
been developed. Each day when samples were analysed, pairs of the 
operators own breath samples were analysed at the beginning and end of 
each "run". In addition, patients samples were repeated with each run (Table 
5.4), and mean and SD evaluated. Every three months, precision was 
checked using the C02 zero 20 method (Figure 5.1) with the reference gas. 
These procedures give confidence in the validity of the DaB results, ie, the 
DaB results after 185 mg labelled triolein was administered remembering that 
the absolute PDB levels at that particular time were not relevant as DaB is 
calculated as (post dose Del13PDB - pre dose DeI13PDB). 
Evaluation of proposed protocol 
The aim of this study has been to develop a test of fat absorption that can be 
performed in an outpatient setting, within the normal working day. 
An adequate response was noted when two volunteers ingested 200 f.!L 13C_ 
triolein and lemon mousse compared with four patients, who ingested lemon 
mousse alone (Figure 5.5). As a comparison, the same volunteer ingested 
Scandishake alone and Scandishake plus 200 f.!L 13C-triolein (Table 5.14, 
Figure 5.6). Again there was a response to the 13C-triolein but a different 
shaped response curve. This is probably due to the different proportions of 
fat, protein and carbohydrate in the meal. 
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Although the results from the volunteers (V1-V18, Table 5.15) cannot be 
directly compared to the patients because they continued with normal activity 
during the test, the results demonstrate the effect of Body Mass Index (BMI) 
on the Del13PDB values. Those with BMI >29 kg/m2, ie, those defined as 
obese were observed to have lower peak DOB values, eg, volunteers V4, V8 
and V15, (Table 5.16). When volunteers results were corrected to a BMI of 
25 (Table 5.17) the distribution of results around the mean was greater than 
without correction, and those with BMI >29 remained as outliers. Differences 
were noted between the male and female volunteers test results (Table 5.18), 
with males having significantly lower peak DOBs than females. Table 5.18 
compares results for males and females, and results for volunteers with BMI 
>29 were excluded. In Table 5.19, results for male and female volunteers are 
expressed as mean ±2SD for peak DOB and for the cumulative 1-4 hour and 
4-6 hour DOB values. However, these could not be used as "normal" ranges 
as the subjects were not resting during the period of the test. 
Two volunteers were retested using the same protocol after intervals of 6 
months and 5 weeks (Figure 5.7). The response curves for the 2 volunteers 
showed excellent reproducibility both in the shape of the curves and peak 
DOB values. 
The patients were classified into four groups on the basis of review of the 
medical notes and the clinical information available (Table 5.20). This review 
was carried out by a member of the medical staff who was unaware of the 
13C-triolein results. Group 1 included those patients with gastrointestinal 
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disorders not usually associated with fat malabsorption, for example, probable 
IBS, lactose intolerance and Joggers diarrhoea. Group 2 consisted of 
patients with disorders which would be expected to lead to fat malabsorption, 
for example, pancreatic insufficiency and untreated coeliac disease, the fat 
malabsorbers. Group 3 included patients with diabetes or BMI >29. Either of 
these could lead to a false interpretation of the breath test results. This group 
also included patients for whom no clinical information was available. In a 
further 2 patients, (Group 4) there was insufficient information to assign them 
to Group 1 or 2 as their disorder can have variable effects on fat absorption. 
The results for all 26 patients studied are shown in Table 5.21. Patients in 
Group 2, ie, those with fat malabsorption, had lower peak DOB (1.74-2.79) 
when compared with patients in Group 1, ie, those with normal fat absorption 
(4.0-6.69). Table 5.22 compares the curve DOB values for these two groups 
of patients, and shows significant differences (p = <0.005) for all three time 
periods assessed. The test as developed in this study is therefore able to 
distinguish between patients with and without fat malabsorption. 
The shape of the response curves produced by the patients (Figure 5.8 and 
Figure 5.9) shows three groups; those whose 13C02 values were still rising at 
6 hours (11 patients), those who had reached a low peak and then fallen 
(mainly Group 2 patients, the fat malabsorbers), and those who reached a 
high peak and then were falling at the 6 hour point. Lembcke using 13C_ 
hiolein (32) noted that the peak occurred 6-9 hours after ingestion of the 
labelled test meal, using a meal comprising a similar amount of fat. They 
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suggested using a measurement at 8 hours after substrate ingestion, 
however, this would be less convenient in an outpatient setting. Turner et al. 
(14) using 14C-triolein and lemon mousse prepared as described in this study, 
observed peak 14C02 excretion within 6 hours in 97% of 61 subjects with 
normal fat absorption. Similar results would be expected when 13C-triolein is 
used instead of 14C-triolein. 
The correlation between the two tests was examined. Figures 5.1 Oa, 5.1 Ob 
and 5.10c compare 14C-triolein expressed as the peak % dose recovered with 
13C-triolein expressed cumulatively for the three time periods, 1-4 h, 4-6 hand 
1-6 h. A wide scatter of results was noted but the cumulative 4-6 h appeared 
to most satisfactorily separate Group 1 and Group 2 patients and gave the 
highest correlation coefficient (0.48) when the two tests were compared in all 
patients studied. 
The data analysis focused on Group 1 and Group 2, the patients in the other 
groups could not be classified as normal fat absorbers or malabsorbers. 
Cumulative data are shown graphically in Figures 5.1 Oa, 5.10 band 5.10c. 
This study has shown the cumulative DOB 4-6 hours gave the greatest 
separation between the groups of patient results. In future protocol 
developments, collection of data at 0, 4, 5, 6 h post dose or at a single post 
dose time could be sufficient to give discrimination between the groups. 
This study could be extended further by investigating the effect of restricting 
the type of food eaten the night before the test and ensuring that no further 
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food is ingested until the end of the test. The activity of the patient prior to 
and during the test is another important factor, this could be investigated 
further by resting the patient before beginning the test and then taking two 
basal breath samples 30 minutes apart. Activity throughout the test should be 
restricted. Additional subjects with normal and abnormal fat absorption need 
to be studied to increase the confidence in the procedure. 
In conclusion, this work has showed that this method using 200 III 13C-triolein 
with lemon mousse as the fat meal can distinguish normal fat absorbers from 
fat malabsorbers and with the collection of data from more patients, this 
method could be one of the routine tests used in a clinical setting for the 
detection of fat malabsorption. 
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7 CONCLUSION AND FUTURE DEVELOPMENTS 
This study has shown that the protocol using 200 ilL 13C-triolein with lemon 
mousse as the fat meal can distinguish normal fat absorbers from fat 
malabsorbers. The cumulative DOB data collected 4-6 hours post dose gave 
the greatest separation between groups of patients results. 
Future workers may wish to restrict further the type of food eaten the night 
before the test and also ensure that no other food is ingested until the end of 
the test. They may also wish to restrict the activity of the patient before and 
during the test. The actual point of testing post dose could also be 
investigated further, only one breath sample at 6 hours post dose may be 
sufficient to discriminate normal fat absorbers from fat malabsorbers. 
During the time of the study, the low numbers of patients referred by the 
Gastroenterologists has hindered data collection. Future workers may wish to 
recruit a doctor who could be more active in recruiting suitable patients for a 
larger study. 
Therefore with the collection of data from a larger group of patients and 
further restrictions in diet and exercise, this method could become one of the 
routine tests used in a clinical setting for the detection of fat malabsorption. 
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APPENDIX I 
Southern Derbyshire Local Research Ethics Committee approval 
Southern Derbyshire r~/:~j--
I~OIIl'(nArn Derbyshire Health Authority 
Local Research Ethics Committee 
Chairman: Or A W A CtossIeCS FRCA 
ActllIfI Admln""'tor: Adrlan ext 6210 (direct dial from Detby hospitals 16-6210) 
Dhct tu: 01332 363963 
em.lI: adrlan.thotpe(jmal'.sdetby-ha.trent.nhs.uk 
4th May 2000 
,",V,lUlIJLU4JUL Biochemist 
IDepartment of Chemical Pathology 
DearDrHill 
SDLREC REF: 0003/154 
Derwent Court 
Stuart Street 
Derby 
DE'2FZ 
TeI: 01332 626300 
Fax: 01332 626350 
DEVELOPMENT OF A FAT ABSORPTION TEST USING A STABLE ISOTOPE LABELLED 
TRIGLYCERIDE (llC-TRIOLEIN) AS A MARKER SUBSTRATE 
The Southern Derbys~ Local Research Ethics Committee considered the above protocol on 28th March 
2000. I am. pleased to be able to inform you that your study was approved on the underStanding that you 
will follow the protocol as agreed. However, the Committee would be grateful if the title on the patient 
infonnation sheet could be simplified. May I remind you that indemnity arrangements and financial 
iinplicationsneed to be agreed with all appropriate Trust management(s) before commencing the triaL 
note that the SDLREC will require: 
to be advised immediately of any adverse report or changes to the protocol or if the study is 
abandoned; 
• a progress repQrt on an annual basis or at the end of the study if this is a lesser time; 
• copies of ¥l p~blished reports. 
For your information, the SDLREC complies with the ICH Harmonised Tripartite Guidelines for Good 
Clinical Practice. In line with Department of Health guidance it has an executive sub committee which 
meets twice a month specifically to consider MREC-approved applications. 
Yours sincerely 
~( , , ... "', , 
~ 
A W A Crossley 
Chairman 
Derbyshire Local Research Ethics Committee 
Or T Grieve, R & D Manager, DCGH 
(hief Ex('wtive: Michael Manhment 
Wpbl/tp' http://www,sdhealth.demon,(O,uk 
APPENDIX 11 
Standard Operating Procedure: 14C-triolein fat absorption breath test 
' .. 
--.------------------------------------------------------------
Derby Pathology SOP - 14C Triolein Breath Test 
No of pages: 6 
Chemical PatholoRY 
.. 
. ,.;, . Expiry date: 30 June 2004 . . 
. . 
AUTHORISEo STANDARD Authorised by: M R Hopton 
dJ1/.k OPERAnNG PROMtJAe Signature 
File Code: - SOP1RIO W' 
Work area:- d5 
:--
1~ - T.riolein Breath Test 
INTRODUCTION 
In this test fat absorption is a~~e(tJ?y~measuring the 14C02 exhaled in the breath 
over a 6 h period after a small oral· dose of 14C labelled triglyceride. 
PRINCIPLE 
In the nonnal process of fat di~on, absorption and assimilation, dietary 
triglycerides are emulsified ,by. b~e .~~ iD. the small bowel and hydrolysed by lipase 
to free fatty acids and monoglycerides which are absorbed. Re-esterification to 
triglycerides occurs in the enterocytes . 
. After transport via the lymphatic and blood systems to the liver, the triglycerides are 
oxidised with the production of CO2 which is subsequently exhaled~ . 
In tile 14C - triolein breath test, a sm~l amount of 14C - triolein (the triglyceride, 
glyceryl - trioleate) is giyt?~(in a t~St.rpeal. 9,flemon mousse containing 20 g of fat. 
The 14C - triolein is incorpo~. in 'th~body's fat pool and oxidised with the 
exhalation of 14C02 . . 
Breath CO2 is trapped by exhalation into hyamine hydroxide; scintillant is added and 
14C activity measured by liquid scintillation counting. .' 
As the test uses 14C, it should only be carried out within the first 28 days after the 
LMP in pre-menopausal women. It is unsuitable for subjects under 16 years of age, 
and in adults with diabetes, thyroid disease, obesity or severe pulmonary disease. 
SPECIMEN TYPE 
End expiratory breath collected into hyamine hydroxide, a CO2 trapping solution. It 
is important to collect the end expiratory air as the tidal volume will contain largely 
room air and will thus not reflect CO2 released from fatty acid metabolism. 
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After assembling t~e tube and scintillation vial containing hyamine hydroxide (see 
figure), the patient should be instructed carefully to breath in, to hold their breath for 
about 5 seconds, to breath out normally and then, without breathing in , to blow the 
air remaining in their lungs, gently through the tube to bubble through the hyamine 
hydroxide solution. 
Note that 4 - 5 breaths may be required to saturate the solution and change the colour 
from blue to colourless. 
REAGENTS AND MATERIALS 
1. Mousse: in freezer in diet section of DRI kitchen. Ask dietician in office if 
unsure. The recipe for the mousse is described in Gut (1987); 28: 694 - 700, 14C -
triolein absorption; a useful test in the diagnosis of malabsorption. Turner J. M. 
et al. (copy attached). 
2. 14C - triolein; glycerol tri [1· - 14C] oleate, code CFA 258, Arnersham 
International; 9.25 MBq, 3.7 MBq/mL. 
;);nJR~im[_f1l~~liE~~8rdafd(\lijttlm~~ijWiitm~~(o~1~rur~llf~~'ijnn!~!:itl~ 
Keep in the fridge in Day Case Unit laboratory (key to fridge in key locker in 
Biochem 1 office). Replace lid promptly and tightly after use to prevent . 
evaporation oftoluene: . . 
3. Hyamine hydroxide, ImollL (note: the Gut paper erroneously describes this 
reagent as hyamine hydroxide 2 mollL). 
4. Ethyl alcohol, absolute. 
5. Hyamine hydroxide (0.5 mollL): mix equal volumes of hyamine hydroxide (1 
mollL) and ethyl alcohol (absolute). 4 mL of this solution contains 2 mmol of 
hyamine hydroxide and will trap 2 mmol of CO2, 
6. Thymolphthalein (500 mg/L), in ethanol. 
7. Scintillant - EMULSIFIER SAFE obtained from Canberra Packard Ltd. Brook 
House, 14 Station Road, Pangbourne, Berks. RG8 7DT. 
8. Breathing tubes: See Appendix 1. 
9. Scintillation vials: Poly - Q vials from Beckman RIIC Ltd, Progress Road, 
Sands industrial Estate, High Wycombe, Bucks HP] 2 4JL. 
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10. Bottled water: supplied by catering stores using n:quisition book. 
STANDARDS I 
The efficiency of the liquid scintillation counter must be checked every 6 months. 
. 
CONI'ROLS 
Not available. 
METHOD DETAll..S , 
You should only carry out this procedure after proper training 
1. Make up 7 vials per patient Pipette 4.0 mL of hyamine hydroxide (0.5 mollL) 
and 100 J1l thymolpbtbalen solution into each vial. 
2. Take mousse out of freezer, allow to thaw in food fridge overnight 
3. Dispense 185 kBq (5uCi), i.e. SOpL, of L4(; -.triolein onto stainless steel teaspoon. 
Recoidbatch number:. Evaporate the toluene from spoon using cold hair dryer. 
4. Put spoon into mousse. 
5. Wash hands thoroughly to avoid possible transfer of 14C on to tubes or vials . ..:, 
6. Ensure that the patient has understood and followed the instructions described in 
the letter to the patient (attached). 
7. Take basal sample BEFORE giving mousse. Ensure that patient breaths out as 
. . 
far as possible (i.e. collect end expiratory air). If solution is mistakenly sucked 
into mouth, wash well with water. 
8. Give mousse. Ensure that patients eats it ALL and that the spoon has been well 
licked. 
9. Give patient a drink of water (to ensure no residual radioactivity is left in the 
mouth). 
10. After I hour collect another breath sample, and continue at hourly intervals until 
a total of 7 samples have been collected. 
11. A lightiunch is permitted 4 hours after the start of the test. 
12. Ensure that patient's height and weight are recorded. 
13. The patient may eat and drink normally after lunch. Smoking is NOT permitted 
at anyt\re durinr ,~e test. 
I'ag[: ; ,lIc) '( I 11 0 ielll Hreath rest 
• 
14. Add 10 mL ~intiUaDt (EMULSIFIER SAFB, Canberra Packard Ltd) and leave 
overnight' 'Cariy out in a fume cupboard and wear gloves. Send to DCGH for 
counting I 
CALCULATION 
The peak COl excn:tionlh is expressed as % of the dose given, based on peak cpm. It 
is calculated as: 
peak c.pm x 9 x body weipt in kg x 100 '* 
2x 1.11 X 107 , 
In borderline cases CO2 excreti0n/3 h expressed as % of the dose, based on the sum of 
4 ~ 5 ~ and 6 h cpm: values, may provide additional interpretative information. It is 
calculated as: 
(4h+ 5 h+6 hcpm)x9 xbodyweigbtinkgx 100 
2x 1.11 X 107 
The derivation for the formulae is given in Gut 1987; 28: 694 -700. 
SPECIAL REQUIREMENTS FOR REAGENT AND SPECIMEN DISPOSAL 
1. For reagent and/or specimen disposal - pipe«etips, other radioactive waste from 
administering the 14C - triolein and the scintillation vials after counting musftbe 
disposed of according to the local rules for the use of Carbon 14 
2. All other reusable equipment must be sterilised for 24 hours in 125 ppmsodium 
hypochlorite solution . 
• 
TECHNICAL DOCUMENTA nON AND VALIDATION 
A written log must be kept of receipt, usage and disposal of 14C - triolein. 
Ensure that a record is kept of patient details, including body weight (kg), and cpm 
for basal and subsequent samples. 
Enter the peak CO2 excretionlh expressed as % of the dose into the computer. Set 
code is BC02. Add appropriate CTEXT comment; 
BC02A: Normal fat absorption is indicated by a value of2.8% or more. 
or 
BC02N: 
"., Result indicates malabsorption of fat. 
Normal fat absorption is indicated by a value of2.8% or more. 
Result indicates normal absorption of fat. 
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CLINICAL AUTHORISATION 
1. Results will be authorised by a senior member of staff prior to printing. 
OUT OF HOURS REQUESTS 
Tbe test is not available out ofbours. 
RANGES 
Normal fat absorption is indicated by a peak CO2 excretionfh expressed as % dose of 
2.8% or more. A cumulative 3 h results of 6.9% or more indicates nonnal fat 
absorption. 
TURN ROUND TIME 
Appointments for out -patients are normally made within 2 weeks of receiving 
requests. The test will be done on in-patients only when there are clear reasons why 
an OP visit is inappropriate. 
Results are available within 48 hours of completion of the test. 
EXTERNAL QA SCHEMES 
Not available 
Author: Dr P G Hill 
Reviewed by: Date: Expiry date: 
ALloyd August 1997 June 1998 
ALloyd June 1998 June 1999 
DrP GRill August 1999 June 2000 
Dr PG Rill September 2000 June 2002 
V Porter August 2002 June 2004 
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DERBY PATHOLOGY 
. 
29 October 1996 Cbemical Patholo&Y Department 
DeIbysIirc RoyalIDfinDllyNHS Trust 
LoadoD Road, DabJ. DB12QY 
Patient's address 
Dear Patient 
Td: 01332 347141 
Please ask for e>cleDsioo 2521 
Fax: 01332 254924 
Dr X has asked me to get in touch with you in connection with a test of fat absorption. 
I would be gratefiJl if you could attend the Day Case Unit at Derbyshire Royal Infirmary on 
Thunday·l0 October 1996 at 9~OO am. On arrival at the .hospi~ follow sigDs. to tile Day 
Case Unit, (see enclosed map), and present the. enclosedfonn at the reception area there; 
Please do not have anything to eat from midnight on Wednesday, ie, 9 hours before coming 
for the test. 
The test consists of eating some mousse after which we will collect breath samples from you 
hourly until about 3.30 pm. Details about the test are enclosed. You can have a cup of tea 
before coming for the test and you can have a light lunch 4 hours after beginning the test and 
for t~ it may be convenient to bring some sandwiches. A book or some other means of 
passing the time would help the day to pass more quickly. 
Ifit is not possible for you to attend on this date, could you ring extension 2521, at the 
Derbyshire Royal Infinnary (347141) as soon as possible to arrange another date, and so that 
your appointment time can be offered to someone else. 
Yours sincerely 
.... -P G Hill, PhD, MCB, FRSC, FRCPath 
Consultant Biochemist 
. I I ,;, It'! I 11/, 
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DERBY PATHOLOGY 
29 October 1996 
WOMEN <50 YEARS 
f' 
Patient's addreSs 
Dear Patient 
• 
CbemiCal PItboIo&Y Department 
Delbysb.lre Royallnfirmuy NHS Trust 
London Road, Deaby. DEI 2QY 
Tel: 01332 347141 
Please ask for extcDsion 2521 
Fax: 01332 254924 
Dc X has asked me to get in touch with you in connection with a test of fat absorption. 
I' would be grateful if you Could attend the Day Case Unit at Derbyshire Royal IDfirinary on 
Thursday 24 October 1996 at 9.00 am. On arrival at the hospital, follow signs to Day Case 
Unit (see enclosed map) and present the enclosed form at the reception area there. Please do 
not have anything to eat from midnight on Wednesday, ie, 9 hours before coming for the test. 
However, as with many other investigations, it is important that this test is not performed if. 
there is any possibility that you are pregnant and we would not wish to do the test if your 
perio~ is overdue or clearly missed. Please let me know if this is the case. 
~ 
The test consists of eating some mousse after which we will collect breath samples from you 
hourly until about 3.30 pm. You can have a cup of tea before coming for the test and you can 
have a light lunch 4 hours after beginning the test and for this it may be convenient to bring 
some sandwiches. A book or some other means of passing the time would help the day to 
pass more quickly. 
If it is not possible for you to attend on this date, could you ring extension 2521, at the 
Derbyshire Royal Infirmary (347141) as soon as possible to arrange another date, and so that 
your appointment time can be offered to someone else. 
y ours sincel~ly 
P G Hill, PhD, MCB, FRSC, FRCPath 
Consultant Biochemist 
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Southern Derbyshire h!f:bj 
Acute Hospitals NHS Trust 
Patient Information 
DERBY PATHOLOGY 
FAT ABSORPTION TEST .. 
The test which your doctor has requested is used to assess the absorption of fat in the bowel. 
You will be asked to blow into a tube, after which you will be given a lemon mousse to eat. 
A very small amount of radioactive fat is added to the mousse. 
Your doctor has given approval for the use of the radioactive fat, which is an unlicensed 
product, but has been used by Derby Pathology since 1982 and is widely used in the UK and 
other countries for this purpose. 
Radioactivity in subsequent breath samples is used to assess the absorption of fat in the 
bowel. The radiation dose is very small and equivalent to less than the radiation from a chest 
x-ray. 
If you have any concerns about the test, please ask your doctor before coming for the test, or 
contact Dr Hill's secretary at the Derbyshire Royal Infirmary (01332 347141, Extension 2521), 
or speak to the health professional who will conduct the test. 
It 
Chemical Pathology Departments - Southern Derbyshire Acute Hospitals NHS Trust 
PAT/0296/0011NERSION1 
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APPENDIX III 
Standard Operating Procedure: 13C-urea breath test 
' .. 
Derby Pathology SOP - 13C-Urea Breath Test 
Np of pages: 4 
Chemical Pathology . , Expiry date: 28 February 2004 
I .. 
A~~~gA~D Authorised by: M R Hopton ';I/f/,~ OPERATING PROeEDUAB!! , Signature 
.. 
File Code: - 13cubt 
Work area: - d5 
13C-Urea Breath Test (capsules) 
INTRODUCTION 
Helicobacter pylori is the most common cause of histological gastritis and probably 
the causative organism of peptic ulcer and gastric cancer. The bacteria has extremely 
high urease levels which is the basis of diagnostic tests for detecting abnonnal gastric 
colonisation. 
This procedure may only be carried outby staff authorised by the group protocol to 
administer 13C-Urea.. . . . . 
PruNCWLESOFMETHOD 
After an oral dose of BC-urea, 13C02 rapidly increases in concentration in the breath 
in H pylori positive subjects. 
The 'breath 13C02 15 minutes after ingestion of a capsule containing 13C-urea is 
compared with the basal breath 13C02 level. . 
13C02 is always present in breath samples and is measured as the ratio of 
\3C02: 12C02, i.e. the ratio of mass 45:44 (with corrections for 170 ). The UBT result 
is expressed as the difference between the ratio at To and T15, multiplied by 1000 (i.e. 
not percent, but per mil): 
(ratio at T 15min - ratio at To min) X 1000 = UBT result. 
The 13C02: 12C02 ratio is measured by isotope ratio mass spectometry (IRMS). 
SPECIMEN TYPE 
End expiratory breath sample collected into 10 mL glass or plastic tube with gas-tight 
cap ( eg Exetainer). 
Page I of4 He - Urea Breath Test 
I 
REAGENTS 
1. 13C-Urea (99 atom %); Cambridge Isotope Laboratories, USA. Available in the 
UK from Torbet Laboratories, Chatham, Kent ME4 4TE (Tel 01634 817790). 
This is a pharmaceutical and must be ordered via Pharmacy DRI. 
. . . ;·':·.u:r~ n:'l~lACJ .. rn !li, 
2. BC-Urea capsules for administration to patients. ' OrdelM' ;'i~"1>'r~acy/b~' . 
current order is for 150 per month (to end of M8!ch .~QQ1J.:i~S't9r~ti:i~~~s'::·· 
fridge in the Pathology Suite of the Day Case Unit. 'It 
3. Exetainers LABCO Ltd, Brown Works, Copyground Lane, High Wycombe, 
Buckinghamshire, England HP12 3 HE (Tel 01494459741) 
4. Carbon dioxide, grade 4.5, Air Products PLC, Special Gases Group, Weston Road, 
Crewe Cheshire (Tel 08457 778800). 
5. Helium BOC, product code 689. 
STANDARD 
The IRMS standardisation is based on PDB (see Breathmat Manual). For the UBT, 
absolute values are not required and the ratios are calculated relative to the standard 
CO2·which is measured between each breath sample. .. 
CONTROLS 
The IRMS operators breath sample is used as a control. 
METHOD DETAILS 
• 
1. Ensure that the patient has understood and followed the instructions described in 
the letter to the patient (attached). 
2. Collect 2 baseline samples as follows. Instruct the patient to hold their breath for a 
few seconds and then to blow through the straw into the base of the Exetainer tube 
(zero time); withdraw the straw as condensation appears inside the tube. Replace 
cap quickly (do not over tighten). Write the patient's name on the tube. Repeat 
with the second tube. 
3. Give the patient ONE l3C-urea capsule, to be swallowed with 20 mL water. They 
should stand while they swallow the capsule and then sit for the 15 minute period. 
4. Collect 2 breath samples as described above, at 15 min after swal10wing the 
capsule. 
5. Check nameslbar codes on pairs of zero and 15min tubes .. The test is now 
completed for the patient. 
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6. Keep the individual patients tubes together ana return them to the laboratory for 
analysis. . 
SPECIAL REQdnmMmrrs 
13e-Urea is not radioactive; there are no special requirements for the disposal of 
waste matciials for this procedure. 
TECHNICAL DOCUMENTATION AND VALIDATION 
13C-Urea is administered as a pharmaceutical. A grQJ1P pr;tocol authorises this 
medicine to be administered by Biomedical Scientists or Clinical Scientists. A copy 
is kept in the Pathology Suite, Day Case Unit OR! and in Special Investigations OR!. 
The 13C-UBT set beading includes the dose of 13C-Urea administered, which is a 
requirement of the group protocol. 
ISOTOPE RATIO MASS SPECfOMETER 
The Breatbmat IRMS is used to measure the breath samples. The analyser software 
calculates the difference between the 15 minute and zero samples 
The adequacy of the breath collection is assessed from the Breathmat readout 
DATA ENTRY 
The set for the capsule based UBT is Cl3UBT. The breath test result from the IRMS 
printout (column marked DOB) is added in SRES to the test field 13CUBT. 
Report minus results as <0.1 (seek advice if any minus results are beyond the range of 
-O.f to -0.6). 
Check that the result has been entered correctly. 
CLINICAL AUTHORISATION 
1. Results will be authorised by a senior member of staff prior to printing. 
2. The following CT codes are available for authorising results: 
13N: for results <0.7 
l3A: for results >0.7 
""~ 
Please note that for project St.lILl·: ... p,.:·~.fic codes may be in use. 
OUT OF HOURS REQUESTS 
The test is not available out of hours. 
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RANGES 
A result greater than 0.70/00 indicates the presence of gastric Helicobacter. 
TURN ROUND TIME 
:I 
Appointments for out-patients are nonnally made within 2 weeks of receiving the 
request unless it is clear that the patient has recently been on Losec (or other PPI' s) or 
antibiotics. The test will be done on in-patients only when there are clear reasons 
why an OP visit is inappropriate. Results are nonnally available within 4 working 
days of completion of the test. 
EXTERNAL QA SCHEMES 
Not available. 
Author: P G Hill June 2000 
Reviewed by: Date: Expiry date: 
A Lloyd May 2002 February 2004 
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APPENDIX IV 
Standard Operating Procedure: BreathMAT IRMS 
. StamM-d Operating Procedure for BreathMAT IRMS 
\3c breath analysis is the most common stable isotope measurement made in nutrition and 
medicine. Measuring \3C enrichment in breath is a routine procedure for laboratories using 
." 
stable isotopes to study human and animal nutrition or performing \3C diagnostic breath 
tests. 
The BreathMAT uses continuos flow isotope ratio mass spectrometry to determine \3C 
enrichment in breath samples. 
Samples ofbreath stored in septum capped gas containers (Labco Exetainer) are sampled 
directly by a needle probe. Container contents are flushed onto a gaS chromatograph 
which separates CO2 from N2 and O2. 
Water is removed by a chemical trap. The pure CO2 flows directly to an on line stable 
isoto}J(!analyser for measurement of its I3Cfl2C ratio. 
Routine running of BreathMA T 
Machine on standby,is always switched on with Helium gas set at low flow rate (l.0 bar), 
CO2 turned off 
• Check qtbmtity of Helium gas (outside lab in Medical gas store, key on the lab notice 
board) and CO2 gas cylinder next to the machine 
• Turn Helium up to 3.0bar 
• Turn C~ on c~k pressure is 4.5 bar 
• Double click instrument control to screen titled BreathMAT control 
add copy of Fig 8 page 11 of Quick start manual 
This shows two windows: 
-
Instrument control window showing cup signal intensities, status messag~ high voltage 
and vacuum readout ( lower half of screen) 
Scan window showing a graph space with intensity and ratio labels. High vohage scans or 
time scans are displayed here 
• Check vohage - 2500 V 
• Check vacuum-1.19 E - 6 
• Check gfeen light on va1co 1o~ source, HV, emission, sample available 
• Check ion source on 
• Toggle standard valve to on 
• Check green light on standard 
• Check Cup 1 -2658 mV 
• Check Cup 2 -3111mV 
• Check Cup 3 ~ 1111 mV 
• Wait 30 minutes to stabilize 
• Toggle to select Scan mode 
40 
• Perfonn Time Scan 0 to 600 seconds ( expand scale using "rubber band" to give 
vertical ratio scale of 10/00 ratio) 
• The "noise" ratio trace should not exceed 1 - 1.5 0/00 
. : . ~:: ~. 
" 
. ~(~/: .~ ~ . 
• Double click on BreatbMWr.f~·· 
• Open options then evaJi.j.·;~~·~'!~~~'t .. :: 
• 
mode(magazine exchange) red is •• ~ mode 
" . ".:.,~ . . 
':' '. 
• Tubes must lJe ... 
"" " .... 
• DO NOT mix types of tubes in one magazine 
.... 
.., 
• A QC sample in duplicate is positioned·at start· and end of run ( operators own breath) 
• Run the sequence module, resuhs will appear 
.• 
. 
• Any barcode miss readsjwit;~,~~" numbers need to be edited in at the end of 
the run 
• Any samples that give an mV value ofless than 500mV will need to be run again using 
the duplicate sample 
• At end of run click sequence then evaluate groups 
• Save work 
""-
• Print results 
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Patient information sheets 
APPENDIX VI 
Consent form 
.. 
DERBY PATHOLOGY 
DEVELOPMENT OF A NEW NON RADIOACTNE FAT 
ABSORPTIOl( TEST 
Information sheet 
. 
We are inviting you to take part in a research study to assist us to develop a new 
test of fat absorption. Our current standard test has been in use for 12 years and 
involves eating a lemon mousse to which a very small amount of radioactive fat 
has been added. The fat from the lemon mousse plus the ;adioactive fat is 
absorbed, and metabolised by the body to produce carbon dioxide. This can be 
detected as radioactivity in the breath. The new test uses exactly the same 
principle, but does not use any radioactive substances. Instead it uses a non 
radioactive fat mar1:c~r which can also be detected as breath carbon dioxide. 
You have been asked to participate in the study because: 
*1 Your doctor has asked us to arrange tests to assess your fat absorption 
*2 Other tests show that you have normal fat absorption 
*3 Other tests show that you may have a problem with fat absorption. 
(*Delete as appropriate) 
, ' 
, , 
We would be very grateful for your help, but you are, of course, free not to take 
part. This will not affect the standard of care you receive. If you are willing to 
help us: 
* you will need to come to the Derbyshire Royal InfIrmary for the test 
" 
* the test will be carried out at the same time a the routine test of fat 
absorption which your doctor has requested 
, (*Delete as necessary) 
The test starts at 9.00 am and finishes at 4.00 pm and is not at all unpleasant, 
although boring! It involves eating a small meal and blowing into a tube to 
collect a breath sample every hour. We recommend that you bring a book to read 
to help pass the time. There are no side effects to the test. 
"i '; ,I ':'I,"e that you will feel able to help us with this study which has been 
, , ;,' r the Southern Derbyshire Ethics Committee. If you have any 
<,' ,;,:' I,. )1ease contact Dr Hill's secretary at the Derbyshire Royal InfirJ1lary, 
(Ol;J3:G 347141, extension 2521). A copy of this form is enclosed for you to keep. 
If you have any questions or concerns about this study, you should discuss them with the 
doctor or nurse involved in your care. If you have any concerns about the way this study is 
being condu,cted, you are welcome to contact the Chairman of the Southern Derbyshire 
Ethics Committee, via the Committee's Administrator, Jill Marshall (telephone 01332 
]6]821). 
I<'A,/,inf()fI)KA/I.llIfi(J(J 
DERBY PATHOLOGY 
I 
DEVELOPMENT OF A NEW NON RADIOACTWE FA'l' 
ABSORPTION TEST 
Consent form 
Name of researcher: DrP G Hill 
Please initial box 
1 
2 
I confirm that I have read and understand the information 
sheet dated 09 03 00 for the above study and have had the 
opportunity to ask questions. 
I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
D 
D 
3 I understand that sections of any of my medical notes may D 
be looked at by responsible individuals from Derby Pathology.. ." 
or from regulatory authorities,where it is relevant to my 
taking part in research~ I give permission for these individ.uals 
to have access to my records. 
4 I agree to take part in the above study. 
.. 
Name of patient 
Name of person taking 
consent (if different from 
researcher) 
Researcher . 
Date 
Date 
Date 
Signature 
Signature 
Signature 
D 
1 for patient, l for researcher, 1 to be kept with hospital notes 
".\Tcotls/l ) 1\. \ I : I I< ,iI' 
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APPENDIX VII· 
Explanation letter to volunteers 
DERBY PATHOLOGY 
EXPERIMENT,TO SHOW THE 13C02:12C02 RATIOS IN HEAL THY 
VOLUNTEERS AFTER A TEST FAT MEAL 
The rules 
1 No food after 12 midnight but you can drink water! 
2 You can have a cup of tea before the start of the test. ~ 
3 Brush your teeth before coming to work. 
4 At time 0 minutes, a breath sample is taken into two glass tubes. 
5 A lemon mousse is ea~ ~;~QQ ;m~~ of.13C triolein (a triglyceride 
labelled with a non radlo8ctive stable Isotope). 
6 Breath samples will be taken every 30 minutes until 3.00 pm. 
7 From 3.00 pm you may eat and drink as nonnal. . 
• 
• 
This test will show how.the fat in the· ~ ~ is dllJe$tedover the 6 hours. If, 
as you are all healthy volunteers, the tat isdigestetfnormally, 13C~ will be detected 
in your breath. The quantity of 13C02 will increase gradualry'until about 5 hourS from 
the start then decrease. 
Hopefully, with your help, we will be able to stop using radioactive 14C-triolein as in 
the present fat absorption test. The test you have taken part in today will replace it. 
Thank.you for your help. 
Alison Lloyd 
Senior MLSO 
14 May 2001 
The study has the approval of the Trust's Research and Development Committee and of the Southern 
Derbyshire Ethics Committee. 
" 
. , 
APPENDIX VIII 
Lemon mousse recipe 
DERBY PATHOLOGY 
RECIPE FOR LEMON MOUSSE USED IN THE FA T ABSORPTION 
BREA THTEST (14) 
Recipe to make 10 portions 
100 g sugar (Silver Spoon produced from sugar beet) 
2-3 lemons, grated rind and strained juice 
400 mL double cream 
30 g ground gelatine 
2 egg whites 
300 mL water 
Method 
1 Dissolve gelatine in some of the measured water. 
2 Add remaining water to lemon juice. 
3 Dissolve sugar in lemon juice, add gelatine and lemon rind. Cool. 
4 Fold in slightly whipped cream. 
5 Beat whites of egg until stiff. 
6 Fold into mixture. 
7 Divide into 10 equal portions. 
8 Label "FAT TEST" and date, freeze. 
Analysis per portion 
Carbohydrate 10 g 
Fat 19.3g 
Protein 1.4 g 
Mousserecipe/DKAl131102 

